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1. Introduction 
1.1 Wall tension 
Among the multiple accomplishments of the French mathematician Pierre-Simon 
Marquis de Laplace, the quantitative description of wall tension in 1806 generally is 
not the first coming into ones mind. However, the wal tension Laplace is law of 
fundamental importance for the cardiovascular system and especially the 
pathophysiology of blood pressure-induced remodelling processes in the vessel wall 
(Lehoux 2006; Haga 2007). Hemodynamic forces, which include transmural blood 
pressure, cyclic strain and fluid shear stress (Figure 1.1), constitute a special category 
of biophysical stimuli that elicit important biological effects in affected cells 
(Gimbrone 1995; Resnick 1995). 
 
 
 
 
 
 
Figure 1.1: Main mechanic forces in the arterial system. Whereas fluid shear stress 
(FSS) mainly affects EC, wall tension is also sensed by SMC 
 
Laplace’s law describes the relation between the transmural pressure difference, 
radius, and thickness of the vessel wall as a tensional force. Thus, the wall tension (σ) 
depends on transmural pressure (Ptm), radius (r) and wall thickness (d) in tubular 
vessels (Glagov 1992) as follows: 
σ = Ptm * r/d  
fluid shear stress 
τ= 4 × η × Q/r³ × pi 
(EC) 
? 
wall tension (Laplace) 
σ∼ ptm × r/d 
(EC and SMC) 
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Regarding this definition of wall tension it becomes evident that chronic mechanical 
overload has several important implications for the vascular system. Faced with 
hypertension, Laplace’s law provides an elegant loophole to evade supra-
physiological wall tension, i.e. wall thickening.  
Indeed, as will be discussed in some detail below, compensatory accommodation to 
high pressure conditions occurs via this mechanism – hypertrophic (conduit arteries) 
or hyperplastic (resistance size arteries) wall thickening ultimately restores basal 
levels of tensile stress (Lehoux 2006) at the costs of an increased total pheriperal 
resistance. Depending on time course and pressure level, vessels respond in two 
principal ways. Besides short term responses to increased perfusion pressures, termed 
pressure-induced myogenic constriction (Meininger 1992), the long-term response is 
recognized as compensatory vascular remodelling accompanying prolonged 
hypertension (Collins 1990; MacMahon 1990; Previtt 2002). Increases of 
intravascular pressure in hypertension lead to cytoskeletal reorganization within 
smooth muscle cells (SMC) and remodelling of the vessel wall, resulting in a 
thickened medial layer with high content of extracellular matrix proteins as well as 
smooth muscle hyperplasia and hypertrophy (Heagerty 1993; Mulvany 1992; Osol 
1995; Lehoux 1998; Previtt 2002). In the course of this process, SMC undergo a 
change from a quiescent and contractile to a synthetic phenotype. This is 
accompanied by migration of SMC into the subendothelial space, where these cells 
organize extracellular matrix components resulting in the formation of a neointimal 
cell layer. Endothelial cells (EC) respond to increases in circumferential wall tension 
with a marked change in the secretion of autacoids leading to adaptation of vascular 
function and structure. Physiologically active relaxing and contracting factors, e.g. 
angiotensin II, endothelin-1, bradykinin, acetylcholine and ANP with a variety of 
additional activietes, e.g. as growth factors, (Sumpio 1990; Suga 1993; Day 1995; 
Harrison 1995; Schiffrin 1999) are synthesized, secreted and metabolized by the 
endothelium and crucially contribute to the development of pressure-induced vascular 
remodelling. 
Although relieving the high levels of wall tension, this process is highly problematic 
in terms of the mechanical properties of the vascular system. Whereas adaptive 
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remodelling in specialized vascular beds, e.g. in leg veins, is clearly physiological, 
pressure-induced remodelling in hypertension finally not only results in a fixed high 
resistance to flow which problematic for cardiac function, but also participates in the 
phenotypical modulation of endothelial and vascular smooth muscle cells, promoting 
vascular damage due to endothelial dysfunction, and, ultimately, atherosclerosis 
(Folkow 1973). This is also reflected by the fact that pressure induced vascular 
remodelling already at initial steps seems to include some pro-inflammatory 
components. For example, expression of pro-inflammatory gene products by EC and 
SMC is observed already in early phases of remodelling (see 1.4). 
At the clinical level, manifest hypertension, i.e., hypertrophy and/or hyperplasia of the 
vessel wall are known to be the most important contributors to the development of 
stroke as well as heart and kidney failure. Moreover, thay play a major role in the 
development of coronary artery disease and consequently myocardial infraction 
(Collins 1990; MacMahon 1990; Perry 1995; Pasterkamp 2000).  
 
Figure 1.2: The vicious cycle of pressure/resistance–induced hypertrophic remodelling 
in the cardiovascular system. In order to stabilize cardiac output (CO), the arteriovenous 
pressure gradient (PAV) must be increased in case of high total peripherial flow resistance 
(TPR). If chronic, this relation results in compensatory and mutual cardiac and arterial 
remodelling finally leading to organ failure (see text). The situation of wall tension increases 
occurring repeatedly in the development of manifest hypertension. 
 
arterial  
wall tension 
cardiac 
work load 
blood pressure 
 
 
CO=PAV x TPR 
 organ failure 
(kidney, brain) 
cardiac failure 
  (DCM, MI) 
resistance 
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Although the end points, i.e., pressure-induced vascular remodelling and 
atherosclerosis, have been well characterized, the onset of the remodelling process is 
still not well understood. How do alterations in wall tension change the phenotype of 
vascular cells? How can a simple mechanic stimulus re-program the whole 
transcriptome of affected cells? 
1.2 Vascular mechanotransduction 
The term “mechanotransduction” refers to the many pathways by which cells convert 
mechanical stimuli into chemical activity (Ingber 2006). Mechanical load increases 
protein synthesis and induces the expression of specific genes (Komuro 1993) as well 
as being a potent stimulus for the secretion of several factors in vascular cells.               
In accordance with this principle, most agents exert their actions by interfering with 
certain molecules of known signal transduction cascades. 
Keeping in mind the several consequences of manifest hypertension, understanding 
the initial and specific signalling events leading to the phenotype changes of vascular 
cells necessary for the onset of remodelling is of high scientific and clinical interest. 
What is known? Focal adhesions are a key factor for detecting and responding to 
mechanical stresses (Davies 2001; Shyy 2002). While the cytoskeleton has an obvious 
role in structural cell integrity and motility, it has become clear in recent years that 
cytoskeletal proteins also transmit and modulate the tension between extracellular 
matrix, focal adhesion sites, and intracellular compartments, thus regulating many 
cellular and biochemical processes as, e.g., signalling to the nucleus. One class of 
receptors that modulates both cell-substratum adhesion and signalling are integrins 
(Burridge 1988; Ingber 1991; Ingber 2002; Ingber 2006). In cultured cells, integrins 
concentrate at focal contacts where they build a transmembrane linkage between 
elements of the extracellular matrix and the cytoskeleton (Burridge 1988; Ingber 
2002; Ingber 2006). Since the integrins do not possess intrinsic signalling activity, it 
is thought that signalling occurs via the ability of  these proteins to regulate activities 
of associated signalling partners (Nix 1997). The initial circumferential stretch, driven 
by a step increase in pressure, also activates stretch-sensitive cation channels. Their 
activation leads to increased levels of intracellular calcium and thus, e.g., to SMC 
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contraction (Davis 1999). Those plasma membrane channels have been suggested to 
be primary stretch sensors in mechanotransduction (Lansman 1987; Morris 1990). 
However, conclusive evidence for their involvement in mechanotransduction is still 
lacking. From that point, different mechanotransduction cascades can be initiated 
according to the nature of the mechanical stimulus perceived. 
During the stimulation of vascular cells by wall tension several kinases are activated: 
focal adhesion kinase (FAK), rho-kinase (ROCK) and MAP kinase pathways    
(Lehoux 1998; Tsuda Y. 2002; Li 2003; Li 2003; Lehoux 2006), finally resulting in 
the activation of stress-inducible transcription factors such as AP-1, C/EBP (Lauth 
2000; Wagner 2000; Cattaruzza 2001; Cattaruzza 2002), CREB, NFκB (Li 2003; 
Lehoux 2006) as well as Sp-1 and Egr-1 (Wilson 1998; Morawietz 1999).  
Although all these pathways and transcription factors participate in the cellular stress 
response to mechanical overload, the activation of factors such as AP-1 or C/EBP, 
also part of other stress processes, e.g. inflammation, is not sufficient to explain the 
highly specific and particular gene expression pattern in EC and SMC in response to 
high levels of wall tension. Recently, we could characterize zyxin, a cytoskeletal 
protein normally associated with focal adhesion contacts to be crucially involved in 
wall tension-induced vascular smooth muscle cell signalling (Cattaruzza 2004). 
1.3 Zyxin in vascular mechanotransduction 
Zyxin is a cytoskeletal phosphoprotein widely expressed in human tissue. It is present 
at sites of cell adhesion contacts, where together with its binding partners: α-actinin 
and vasodilator-stimulated phosphoprotein (VASP), it is responsible for the integrity 
and dynamics of the actin fibre formation (Crawford 1991; Crawford 1992; Reinhard 
1995; Hoffman 2006). When cells are exposed to mechanical stress, zyxin relocates to 
actin stress fibres and helps to reinforce the cytoskeleton (Yoshigi 2005). Additional 
to its architectural function, zyxin has been already proposed to potentially be capable 
of participating in intracellular signalling (Sadler 1992; Beckerle 1997). However, the 
generation of zyxin-deficient mice (Hoffman 2003) did not reveal any functional 
phenotype. Affected mice are viable, although they seem to be smaller than wild type 
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mice. Thus, the function of zyxin still is not fully analyzed and might only be revealed 
in pathological models.  
What makes zyxin so remarkable in terms of mechanotransduction? Sequence 
analysis revealed that zyxin has a specific modular organization, consisting of 
functional actA- and LIM-domains as well as a nuclear export signal (NES)           
(Sadler 1992; Schmeichel 1994; Nix 1997). These domains have been shown to be 
involved in direct association with VASP or α-actinin (Reinhard 1995; Gertler 1996) 
and  otherspecific protein-protein or protein-nucleic acid interactions (Schmeichel 
1994) as well as being functional in nuclear export (Nix 1997). Although the structure 
is reminiscent to signalling molecules (Figure 1.3), the function of zyxin in cellular 
signalling is not well understood. However, isolated domains overexpressed in cell 
culture shuttle between focal adhesions and the nucleus (Nix 1997). Moreover, zyxin 
can be activated by ANP in cardiomyocytes and leave focal adhesions (Smolenski 
2000; Kato 2005). Finally, we were able to show for the first time in vascular SMC 
that in response to mechanical stress zyxin indeed relocates to the nucleus of those 
cells, where it may alter transcriptional patterns (Cattaruzza 2004).  
Thus, zyxin is a protein that may specifically transduce mechanical stimuli between 
cellular compartments and the nucleus, not only being part of the sensing machinery 
but also orchestrating the transcription of vascular cells exposed to mechanical stress. 
 
 
 
 
 
 
Figure 1.3: Domain structure of zyxin. 
 
INTRODUCTION   
 
7 
1.4 Wall tension-induced gene expression 
Levels of circumferential strain exerted on vascular cells are a result of arterial wall 
expansion due to pressure-induced wall tension and contraction. To compensate 
supra-physiological levels of this tensile force, several signalling pathways (see 
above) are activated in vascular cells resulting in altered gene expression (Lehoux 
1998; Lehoux 2006). However, up to now, only a limited number of stretch-
responsive genes have been characterized and no valid systematic analysis of the 
endothelial and smooth muscle cell transcriptome in response to increases in wall 
tension has been published. Many of the already known stretch-induced gene products 
encode proteins involved in the environmental adaptation of the affected cells. 
Therefore, identification of all differentially expressed genes under conditions of high 
wall tension would be of high interest in order to gain a first functional insight into the 
initial signalling mechanisms and phenotypic changes of vascular cells during 
vascular remodelling.  
In EC, an increase in cyclic stretch has been proposed to induce the expression of 
several pro-angiogenic and pro-inflammatory gene products such as vascular 
endothelial growth factors (VEGF), cell adhesion molecules (ICAM-1, VCAM-1) and 
chemokines (MCP-1), which in turn lead to subsequent changes in the structure of the 
vessel wall (Resnick 1995; Obuwole 1997). At least some of these gene products as 
well as a number of heat shock proteins (Frye 2005) are, however, regulated by wall 
tension-induced oxidative stress. Oxidative stress, brought about by the activity of 
NAD(P)H oxidase, is also found in inflammation (Griendling 2000; Schiffrin 2003) 
and other cellular stresses. Although this enzyme promotes remodelling, it is thus not 
specific for mechanotransduction. In SMC, VEGF was the first gene identified as 
mechanically inducible (Feng 1999). Further, in human and rat SMC also genes such 
as cyclooxygenase-1, plasminogen activator inhibitor-1, the B-type endothelin 
receptor, matrix metalloproteases and matrix proteins, e.g. fibronectin and tenascin-C, 
have been classified to be mechano sensitive (Feng 1999; Cattaruzza 2004). 
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1.5 The role of natriuretic peptides in cardiac and vascular 
remodelling 
Although zyxin seems to be the long sought-after mechanotransducing protein, one 
important question remains to be answered: How does wall tension activate zyxin and 
induce its nuclear translocation? 
Blood vessels possess a variety of autocrine and paracrine mechanisms enabling them 
to immediately react to local modifications of hemodynamic forces including wall 
tension changes. As pointed out before, cardiac and vascular cells sense such forces 
and secrete various vasoactive substances to regulate vascular tone and maintain 
homeostasis (Lüscher 1986; Lüscher 1986; Moncada 1991; Cohen 1995; Kojda 1999; 
McIntyre 1999). Thus, besides systemic parameters such as sympathetic activity, local 
mechanisms participate in a truly autonomic way to maintain of vascular function and 
structure. 
Interestingly, an apparently unrelated systemic control circuit regulating total body 
fluid and osmolarity employs the sensing of wall tension in cardiac atria in order to 
determine total blood volume (Kramer 1986, Zisfein 1986, Dietz 1989). Besides the 
main “savers” of salt and water, the renin-angiotensin-aldosteron system (RAAS) and 
the anti-diuretic hormone vasopressin, the system is composed of salt and fluid 
“eliminators”, namely three natriuretic peptides (NP): ANP, BNP and CNP together 
with three functionally distinct receptors (NP-R) of the A, B and C-type (Koller 
1992). 
The release of ANP, BNP and CNP from the atria is triggered by increases in atrial 
filling and, consequently, wall tension. Those molecules then promote sodium and 
water excretion by increasing the rate of glomerular filtration and inhibiting sodium 
reabsorption by the kidney (Laragh 1985). Moreover, ANP-mediated actions are also 
characterized to cause prominent increases in endothelial permeability (Brenner 1990; 
Wijeyaratne 1993). Therefore, increased ANP levels are detected in individuals 
suffering form congestive heart failure, chronic renal failure and in severe essential 
hypertension (Koller 1992; Ruskohao 1992; Yandle 1994) presumably to stabilize 
renal function and relieve the cardiovascular system of increased (blood) volume. 
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Most intriguing in the context of vascular mechanotransduction is the mode as to how 
the first NP characterized, atrial natriuretic peptide, is released from atrial myocytes 
into the blood (Ruskoaho 1886; Lang 1985; Kinnunen 1993; Dietz 2005). According 
to these authors, the main physiological stimulus for increased ANP release is a supra-
physiological distension of the atria, caused by increased filling pressures (see 
Laplace’s law), which always occurs when blood volume is elevated. 
Several lines of evidence show that indeed endothelial cells are indeed the atrial 
sensor for increases in wall tension responding with the release of the vasoconstricting 
peptide endothelin-1. Consecutively specialized atrial myocytes are induced to release 
ANP into the blood (Mäntymaa 1990; van Wamel 2001) via activation of the A-type 
ET-1 receptor. In the isolated perfused rat heart ET-1 increases both basal and wall 
stretch-induced atrial ANP secretion (Mäntymaa 1990; Shirakami 1993).  
ANP exerts its physiological responses through binding to a specific membrane-
bound receptor with intrinsic guanylyl cyclase activity (de Bold 1981; Goetz 1988; 
Maack 1992), also referred to as natriuretic peptide receptor type A (NPR-A) 
(Garbers 1991; Garbers 1994). NPR-A-derived cGMP in turn activates the 
downstream cGMP-dependent effector-kinase PKG. Many studies demonstrate that 
NPR-A is the specific and only receptor mediating the hypotensive and 
diuretic/natriuretic actions of ANP (Lopez 1997). ANP however has a low affinity for 
the B-type natriuretic peptide receptor (NPR-B) which appears to be activated 
preferentially by CNP (Garbers 1994). The C-type natruretic receptor (NPR-C), also 
called clearance receptor, does not seem to be involved in important biological effects 
of natriuretic peptides, and is thought to serve as a “scavenger” receptor for 
eliminating excess ANP by internalizing it (Maack 1987; Maack 1992). All NP 
receptors and signalling pathways are summarized in Figure 1.4. 
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Figure 1.4:  Schematic representation of the natriuretic peptides, their receptors and 
their intracellular signalling pathways. 
 
 
Since several components of this complex multi-cellular cardiac mechanosensing 
machinery are expressed in the vasculature, especially in EC, we have analysed if 
these proteins also mediate the onset of wall tension-induced signalling in human 
cultured primary endothelial cells.  
  
clearance of 
natriuretic peptides 
NPR-A NPR-B NPR-C 
ANP, BNP CNP ANP, BNP, CNP 
PKG 
GTP GTP cGMP cGMP 
GC 
? 
NPR-B 
(blood vessels, bone, 
fibroblasts) 
(bone) growth regulation 
vasorelaxation 
anti-proliferative 
NPR-A 
(ubiquitous, epithelia, EC, 
muscle cells) 
diuresis / natriuresis,  
vasorelaxation 
anti-hypertrophic /  
anti-proliferative 
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1.6 Aims of the study 
As described, the cytoskeletal protein zyxin is an integral part of (pathophysiologic)                             
mechanotransduction in vascular cells. In rat aortic smooth muscle cells zyxin is 
activated upon mechanical overload, then translocates to the nucleus and is involved 
in the first steps of vascular remodelling – stretch induced gene expression 
(Cattaruzza 2004). Although an association of wall tension and zyxin in mediating 
intracellular signalling in vascular cells has been defined, molecular mechanisms of 
this process remain fully unexplored. It is not yet clear whether zyxin is a 
mechanosensor itself or is an early protein in the specific response pathway. 
In order to understand the role of zyxin in vascular mechanotransduction, this work 
will address three main issues:  
First, how is zyxin activated in response to increased levels of wall tension in 
endothelial cells?  
Secondly, what are the principal changes in gene expression in endothelial and 
smooth muscle cells in response to wall tension? Moreover, what role does zyxin play 
in wall tension-induced gene expression? To answer these questions, we will use 
human cultured primary EC and an siRNA-mediated zyxin knock down approach as 
well as aortic SMC derived from wild type and zyxin-deficient mice. These cells will 
be exposed to cyclic stretch (equivalent to an increase in vessel radius, see Laplace’s 
law) and characterized by systematic genome-wide micro-array analyses.  
Thirdly, the role of zyxin in vascular function will be explored using a perfusion 
chamber and femoral arteries freshly isolated form wild type and zyxin-deficient 
mice. 
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2. MATERIALS  
2.1 Synthetic oligonucleotide primers for PCR 
The oligonucleotide primer sequences for all gene products used in real time PCR 
gene expression analysis are listed in table 1. Oligonucleotides were synthesized by 
IBA (Göttingen, Germany) and dissolved in water to a final concentration of              
1 nmol/µl. 
Table 1: PCR DNA primers 
Gene product
 
Primer sequence (forward/reverse) Annealing temperature (°C) 
Mouse MCP-1 
(Demicheva) 
5´ -TTC CTC CAC CAC CAT GCA G- 3´ 
5´ -CCA GCC GGC AAC TGT- 3´ 60 
Mouse AT-1 
(own) 
5´ -TGT TCC TGC TCA CGT GTC TC- 3´ 
5´ -CAT CAG CCA GAT GAT GAT GC- 3´ 60 
Mouse ETA-R 
(own) 
5´ -CTA AGC AGC CAC ATG GAA GA- 3´ 
5´ -CCA TTG CTA GGC AGG GCC AA- 3´ 60 
Mouse ET-1 
(own) 
5´-GCG TCG TAC CGT ATG G- 3´ 
5´-TGG TGA GCG CAC TGA C- 3´ 58 
Human IL-8 
(own) 
5´ -TAG CCA GGA TCC ACA AGT CC- 3´ 
5´ -GCT TCC ACA TGT CCT CAC AA- 3´ 60 
Human CXC3L1 
(own) 
5´-TCT GAA GGC TGG GTT CTG AT- 3´ 
5´ -TGT CAG GGG GAC AGG TAT TC- 3´ 58 
Human IL-8 receptor 
(CXCL1) (own) 
5´ -TCC TGC ATC CCC CAT AGT TA- 3´ 
5´ -CTT CAG GAA CAG CCA CCA GT- 3´ 58 
Human VCAN 
(own) 
5´ -CAA GCA TCC TGT CTC ACG AA- 3´ 
5´ -TGG TTG GGT CTC CAA TTC TC- 3´ 60 
Human VCAM-1 
(own) 
5´ -CAT GGA ATT CGA ACC CAA ACA- 3´ 
5´ -GAC CAA GAC GGT TGT ATC TCT GG- 3´ 60 
Human ICAM-1 
(own) 
5´ -TGA TGG GCA GTC AAC AGC TA- 3´ 
5´ -GGG TAA GGT TCT TGC CCA CT- 3´ 60 
Human GAPDH  
(Wagner et al) 
5´ -GAC CAC AGT CCA TGC CAT CAC TGC- 3´ 
5´ -ATG ACC TTG CCC ACA GCC TTG G- 3´ 60 
Human NPR-A 
(own) 
5´ -AAC GCA TTG AGC TGA CAC G- 3´ 
5´ -GTC CAG GGT GAT GCT CTC AT - 3´ 58 
Human NPR-C 
(own) 
5´ -AGT GAG ATG GCT ATG GAG G- 3´ 
5´ -TCC TCC ATA TTG AGC CCT TG- 3´ 58 
Human ANP 
(Wagner) 
5´ - GAT AAC AGC CAG GGA GGA CA - 3´ 
5´ - ATC ACA ACT CCA TGG CAA CA - 3´ 60 
Human BNP 
(Wagner) 
5´ - TTA CAG GAG CAG CGC AAC C - 3´ 
5 – GGA CTT CCA GAC ACC TGT GG - 3´ 58 
Human CNP 
(Wagner) 
5´ - TCG CCT TCT GCA AGA GCA C - 3´ 
5´ - GAT TCG GTC CAG CTT GAG G - 3´ 60 
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Mice WT zyxin 
(genotyping) 
5′-TAC AAG GGC GAA GTC AGG GCG AGT G-3’ 
5′-TGG ACG AAG TTT CCG TGT GTT G-3′ 58 
Mice NEO zyxin 
(genotyping) 
5′-GAC CGC TTC CTC GTG CTT TAC-3′ 
5′-TGG ACG AAG TTT CCG TGT GTT G-3′ 58 
 
2.2 Bacterial strains and plasmids 
Table 2: Plasmids 
Vector
 
Characteristic Source 
pCR 2.1-TOPO 3.9  
pUC origin, lacZα reporter fragment; T7 
promoter/priming site, f1 origin; ampiciline 
resistance ORF; kanamycin resistance ORF 
Invitrogen 
(Karlsruhe, Germany) 
 
Table 3: Chemically competent E. coli cells 
Bacterial cells
 
Genotype Source 
One Shot TOP10F´  
 mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 
∆lacX74 recA1 araD139 ∆(ara-leu)7697 galU galK 
rpsL endA1 nupG 
Invitrogen 
E. cloni 10G  
F´mcrA ∆(mrr-hsdRMS-mcrBC) endA1 recA1 Φ 
80dlacZ∆M15 ∆lacX74 araD139 ∆(ara,leu)7697 
galU galK rpsL nupGλ tonA 
Lucigen 
Corporation 
(Middleton, USA) 
 
2.3 Small interfering RNAs 
Table 4: siRNA target sequences constructed by Qiagen 
siRNA
 
Target sequence Source 
Hs_ZYX_1_HP 
Validated  AAG GTG AGC AGT ATT GAT TTG 
Qiagen 
(Hilden, Germany) 
AllStars Negative 
Control  N/A Qiagen 
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2.4 Antibodies 
Table 5: Regularly used secondary antibodies 
Secondary antibody and specification Source  
Alexa Fluor 488 goat anti-mouse and anti-rabbit IgG MoBiTec (Göttingen, Germany) 
Alexa Fluor 594 goat anti-rabbit IgG MoBiTec 
Goat anti-rabbit IgG peroxidase  Sigma Aldrich (Schnelldorf, Germany) 
 
Table 6: Primary antibodies 
Primary antibody and specification Source  
Mouse anti-human eNOS /NOS-3 BD Transduction Laboratories (California, USA)  
Rat anti-mouse CD31 clone MEC 13.3, polyclonal Santa Cruz Biotechnology (Heidelberg, Germany) 
Mouse anti - β-actin Sigma Aldrich 
Rabbit anti-human B72 LH-ZyxinPLAG (against peptide 
CDFPLPPPPLAGDGDDAEGAL, zyxin amino acids 70 to 89) 
Mary Beckerle, Huntsman 
Cancer Research Centre, 
University of Utah  
Rabbit anti-human B71 LH-ZyxinNES (against peptide 
CSPGAPGPLTKEVEELEQLT, zyxin amino acids 344 to 363) 
Mary Beckerle, Huntsman 
Cancer Research Centre, 
University of Utah 
Mouse anti-human Atrial Natiuretic Peptide, monoclonal Chemicon Europe (Hampshire, UK) 
Rabbit anti-human alpha Atrial Natiuretic Factor (1-28), 
monoclonal 
Penisula Laboratories INC 
(San Carlos, California, USA) 
Rabbit anti-human Atrial Natiuretic Factor (1-28) AbCam 
 (Cambridge, UK) 
anti-mouse eNOS /NOS-3 BD Pharmingen (San Diego, California, USA) 
Mouse anti-human Natriuretic Peptide Receptor type C, 
polyclonal 
Abnova 
(Taipel, Taiwan) 
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2.5 Cell culture. 
Table 7: Cell culture media, buffers, antibiotics and supplements 
Name of product
 
Company 
Collagenase Sigma Aldrich 
Dispase Böhringer  (Mannheim, Germany) 
D-MEM + GlutaMAX-I Invitrogen  
Endothelial cell growth supplement (ECGS) Promocell (Karlsruhe, Germany) 
FBS Invitrogen  
Gelatine Sigma Aldrich 
Hank’s BSS PAA (Cölbe, Germany) 
M199 + GlutaMAX-I Invitrogen 
OPTIMEM I Promocell 
Penicillin Invitrogen 
SMC growth media Promocell 
Supplemental Mix Promocell 
Streptomycin Invitrogen 
2.6 Mouse strains 
C57BL/6J mice were initially ordered from Charles River Laboratories, Sulzfeld, 
Germany, and further bred in the animal facility of the University of Heidelberg. 
Zyxin null mice (line zyxin-185) were kindly provided by Dr. Laura Hoffman and Dr. 
Mary Beckerle from the Huntsman Cancer Research Centre, University of Utah,           
Salt Lake City, USA. Further, the zyxin null mouse line was sanitized to be housed at 
the animal facility at the University of Heidelberg. Animals were studied in 
compliance with institutional and legislatory regulations. 
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Table 8: Mouse strains  
Strain
 
Source 
C57BL/6J Charles River Laboratories, Sulzfeld, Germany 
C57BL/6J zyxin (-/-)  null (line 185) Huntsman Cancer Research Centre, University of Utah, Salt Lake City /JBF 
 
 
2.7 Kits 
Table 9: Kits 
Name Company 
QIAprep Mini Plasmid Kit Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit Qiagen 
Rneasy Mini Kit Qiagen 
Sensiscript RT Kit Qiagen 
QuantiTect SYBR Green® Kit Qiagen 
ReadyPrep Protein Extraction Kit 
(Cytoplasmic/Nuclear) 
BioRad  
(München, Germany) 
ReadyPrep 2-D Cleanup Kit BioRad 
TOPO TA cloning Kit Invitrogen 
Human Endothelin-1 ELISA Kit R&D Systems (Wiesbaden, Germany) 
Human CXCL8/IL-8 ELISA Kit R&D Systems 
Human pro-ANP ELISA kit Biomedica (Graz, Austria) 
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2.8 Reagents  
Table 10: Regularly used reagents and substances 
Substance Company 
Acetylcholine chloride, minimum 99% TLC Sigma Aldrich 
Angiotensin II, human Calbiochem (San Diego, California, USA) 
Atrial Natiuretic Factor 1-28, human Calbiochem 
Bio-Lyte 3-10 Ampholyte BioRad 
BQ-788 Sigma Aldrich 
DETA/NO Sigma Aldrich 
ECL Plus Western Blotting Detection reagent Amersham (Little Chalfont Buckinghamshire, UK) 
Endothelin 1, human and porcine, Calbiochem 
MATra-si Reagent IBA (Göttingen, Germany) 
®-(-)Phenylephrine hydrochloride Sigma Aldrich 
Phosphatase Inhibitors Active Motif (Rixensart, Belgium) 
Protein phosphatase 1 (PP1) New England BioLabs (Ipswich, MA, USA) 
Proteinase K Sigma Aldrich 
RNAlater RNA stabilization reagent Qiagen 
Rp8pGPT-cGMPS Calbiochem 
Taq Polymerase Bioron (Ludwigshafen, Germany) 
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2.9 Solutions and buffers  
Phosphate Buffered Saline (10X) pH 7.4: 
130.0 mM      NaCl 
    2.7 mM      KCl 
    7.0 mM      Na2HPO4 x 2H2O 
    4.0 mM      KH2PO4 
Tris Buffered Saline, pH 7.4: 
  25.0 mM     Tris-HCl 
137.0 mM     NaCl 
    2.7 mM     KCl 
TEN Buffer: 
  10.0 mM     Tris/HCl (pH 8.0) 
    1.0 mM     EDTA 
100.0 mM     NaCl 
 
 
2.10 Microbiological media 
Luria-Bertani (LB) Medium (pH 7.0) 
1.0 % (w/v)   Bacto-tryptone 
0.5 % (w/v)   Yeast extracts 
1.0 % (w/v)   NaCl 
LB-Agar Plates 
1.0 % (w/v)    Bacto-tryptone 
0.5 % (w/v)    Yeast extracts 
1.0 % (w/v)    NaCl 
1.5 % (w/v)    Agar 
 
The Luria-Bertani medium was prepared with distilled water, autoclaved and stored at 
room temperature. LB agar (50° C) was supplemented with 50 µg/ml ampicillin and 
poured into Petri dishes. The dishes were stored at 4° C. 
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2.11 Software  
Table 11: Frequently used software and programs 
Software/Program Company 
KCjunior™ Software BIO-TEK Instruments (Winooski, Vermont, USA) 
LightCycler™ software version 3.5.3 Roche (Mannheim, Germany) 
MyoView™ Pressure Myograph software Danish Myo Technology (Atlanta, USA) 
MetaMorph® imaging system version 3.5 Universal Imaging Corporation  (Marlow Buckinghamshire, UK) 
NanoDrop® software NanoDrop (Wilmington, USA) 
Quantity One® 1-D analysis software BioRad (USA) 
Quantity One® image acquisition software BioRad 
PDQuest™ 2-D Analysis Software BioRad 
InStat statistics program GraphPad Software, Inc (S. Diego, USA) 
BLAST (Basic Local Alignment Search Tool) 
www.ncbi.nlm.nih.gov 
National Center for Biotechnology Information 
(NCBI) 
ExPASy tool 
www.expasy.ch SwissProt 
P-87 Flaming/Brown Micropipette Puller Slutter Instrument Company (Novato, USA) 
SAS MicroArray Solution version 1.3 SAS Institute Inc. (Carry, NC, USA) 
Gene set Enrichment Analysis (GSEA) Broad Institute of MIT and Harvard (USA). 
KEGG database KUBiC, Kanehisa Laboratory (Kyoto, Japan) 
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3. Methods 
3.1 Cell culture 
3.1.1 Isolation and culture of mouse aortic smooth muscle cells 
(mAoSMC) 
Isolated mouse aortae were cut into small rings (1 mm) and washed several times with 
HBSS/Hank´s buffer until all blood was removed. The tissue was digested overnight 
at 37° C, 5 % CO2 in 1.4 ml SMC growth medium containing 5% FBS and 250 µl of a 
1 % collagenase solution in 40 mm ø culture dishes. The resulting cell suspension was 
centrifuged for 5 minutes at 1000 rpm. The pellet was resuspended in 2 ml of SMC 
growth medium (50% D-MEM + GlutaMAX-I Medium, 50% Smooth Muscle Cell 
Growth Medium, supplemented with 5% FBS, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 0.25 µg/ml fungizone antimycotic) and seeded into a 6 cm ø culture 
dish. The cells were cultured using standard cell culture techniques. After passage 1, 
SMC growth medium was replaced by SMC culture medium (D-MEM, supplemented 
with 15% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin and 0.25 µg/ml fungizone 
antimycotic). Cells were incubated at 37º  C, 5% CO2, in a humidified atmosphere. 
Every batch of isolated and cultured mouse aortic smooth muscle cells was tested for 
expression of specific SMC markers including SMC isoforms of α-actin by 
immunofluorescence analysis. Typically, cells were 90% positive for α-SM-actin and 
were essentially negative for the endothelial cell marker vWF. 
3.1.2 Isolation and culture of human umbilical vein endothelial cells 
(HUVEC) 
Human umbilical vein endothelial cells (HUVEC) were isolated routinely from fresh 
human umbilical cords as described in Lienenlüke et al. (Lienenlüke 2000). Briefly, 
umbilical veins were gently flushed with Hank’s buffer solution until they were 
essentially blood-free, filled with dispase solution until the cord was moderately 
swollen and incubated for 30 minutes at 37° C. Veins were then again flushed with 
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Hank’s buffer and the suspension containing the isolated cells was collected in a 
sterile 50-ml tube. The cells were then centrifuged at ambient temperature for                 
5 minutes at 1000 rpm. The sedimented endothelial cells were then resuspended in 
HUVEC culture medium consisting of M199 medium supplemented with 120 mM 
TES-HEPES pH 7.3, 20% fetal bovine serum, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 0.25 µg/ml Fungizone antimycotic and 4 µl/ml endothelial cell growth 
supplement (ECGS) containing 22.5 mg/ml heparin. The cells were routinely cultured 
on standard plastic dishes or collagen type I BioFlex elastomer plates (Flexcell® 
International Corporation) additionally coated with 2% (w/v) gelatine in 0.1 N HCl. 
Culture medium was changed at two-day intervals. The purity of HUVEC was >95% 
as tested by immunofluorescence analysis using vWF as an EC marker. The cells 
were essentially free of α-SM-actin (< 1%).  
3.1.3 Transfection of HUVEC with siRNA 
HUVEC were efficiently transfected with short interfering RNA (siRNA; see Table 4) 
using magnet-assisted transfection (MATra, IBA). Briefly, to transfect one well of a 
6-well plate, 3 µg of siRNA (Qiagen) was diluted in OPTIMEM I medium to give a 
final volume of 200 µl for each well to be transfected (final concentration 
approximately 30 nM). For the formation of the transfection complex, 3 µl of MATra-
si reagent (IBA, Göttingen) was added to the diluted siRNA, carefully mixed and 
allowed to incubate at ambient temperature for 25 minutes. HUVEC were once 
washed in OPTIMEM I, the medium was discarded and then fresh OPTIMEM I (2 ml 
per well) was added to the cells. The siRNA/magnetic beads were then layered 
dropwise onto the cells (200 µl/well). Cells were incubated with the transfection 
complex on a custom-made magnetic plate which was specifically designed to fit the 
wells of the Flexcell plate (Universal Magnet Plate, IBA) for 15 minutes in the cell 
incubator to allow beads to penetrate the target cells. Thereafter, to induce rapid zyxin 
turn over, cells were shortly exposed to cyclic stretch (30 minutes, 0.5 Hz, 10% 
elongation). After this manoeuvre, the medium was changed to prevent cytotoxic 
effects from the transfection reagent, and the cells were kept further under their 
normal culture conditions. Gene silencing was optimal 72 hours after transfection. 
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Therefore, experiments with transfected HUVEC were performed 72 hours post 
transfection. 
3.1.4 Mechanical Strain 
The Flexercell® strain unit was used as a model to mimick the effects of vascular wall 
tension. Endothelial cells (EC) were cultured on flexible membranes of BioFlex® 
Plates (Flexcell® International Corporation, Hillsborough, USA) which can be 
stretched in a defined manner. Before starting the experiment, EC were growth-
arrested for 2 hours in HUVEC quiescence medium. Depending on the experimental 
conditions, defined cyclic stretch was applied to the cells using the computer-assisted 
Flexcell® Tension™ system FX3000T (Flexcell® International Corporation). 
All strain protocols were performed at a frequency of 0.5 Hz using stretch profiles up 
to 10% cyclic elongation for up to 18 hours. Messenger RNA or cellular protein was 
harvested at specific time points after the initiation of stretch. Alternatively, the cells 
were fixed with either methanol/acetone or 4% formaldehyde in PBS for further 
immunofluorescence analysis, or proteins were isolated from the supernatant of the 
cells. 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic diagram of the FlexCell model (A) and a typical strain profile (B) 
applied to mouse smooth muscle cells (SMC) or human endothelial cells (EC) in culture. 
 
3.1.5 General experimental procedures with cultured cells  
Cells were incubated with or without ANP (1 nM) or ET-1 (10 nM) in the presence or 
absence of BQ788 (1 µM) or Rp8pGPT-cGMPS (100 µM) respectively. Reagents 
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were added to the cell culture medium (volume 2 ml). After treatment cells were kept 
at static conditions or exposed to cyclic stretch for 6 hours. Thereafter cell culture 
media were collected and frozen at -80°C for further analysis. Cells were either lysed 
with RLT buffer (Qiagen) for mRNA isolation, fixed as described above for 
fluorescence analysis or collected by centrifugation (3000 rpm, 4°C) for cell 
fractionation and Western blot analysis. 
3.2 Molecular biology  
3.2.1 Isolation of genomic DNA from mouse tails for PCR 
genotyping. 
DNA isolation from the tails was performed according to a standard protocol (Hogan 
1993). From 0.7 to 1 cm of the mouse tail was incubated in 150 µl digestion buffer 
containing proteinase K (1 mg/ml) at 55° C for 6 hours. Every hour the samples were 
mixed to facilitate tissue degradation. Thereafter, the digestion mixture was incubated 
at 95°C for 10 – 20 minutes, gently mixed and centrifuged at 13000 rpm for 10 
minutes at ambient temperature to collect undigested tail debris. Finally, the DNA 
containing supernatant was stored at -20° C for further PCR analysis (see 3.2.9.4).  
For PCR genotype analysis zyxin mice primers (mice WT zyxin and mice NEO 
zyxin) were used (Table 1). The program was as follows (Table 12). The PCR 
products were either wild type zyxin, (327 bp) or null mutant (473 bp). 
 
 
Table 12: Program for genotyping  
PCR step Temperature ( in °C) Time 
Denaturation 95° C 60 seconds 
Annealing 58° C  30 seconds 
Extension 72° C 50 seconds 
 
95° C 1 minute 
Final extension 72° C 3 minutes 
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Digestion buffer for tail DNA: 
670.0 mM       Tris/HCl, pH 8.8 
166.0 mM       ammonium sulphate 
  65.0 mM       MgCl2 
    1.0 % (v/v)  β-mercaptoethanol 
    0.5 %          Triton X-100 
 
3.2.2 Isolation of total RNA from tissue samples and cultured cells 
To isolate total RNA from cells, the QIAGEN RNeasy kit was used according to      
the manufacturer’s instructions. In order to avoid any RNase activity, RNase-free 
water and RNase-free reaction tubes were used during the procedure. Briefly, total 
RNA was extracted by adding 350 µl of lysis buffer containing 1%                               
β-mercaptoethanol per well of a 6-well plate. Thereafter, lysates were scraped from 
the wells into microcentrifuge tubes and homogenized for 30 seconds. An equal 
volume of 70% ethanol was added and mixed with the lysates. The mixture was then 
transferred to the mini spin column, centrifuged for 25 second at 13000 rpm following 
two washing steps. Finally, the RNA was eluted with 30 µl RNase-free water. 
3.2.3 Determination of nucleic acid concentration 
The concentration of nucleic acids was determined spectrophotometrically using      
the NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, USA) by 
measuring light absorption at 260 nm. Nucleic acid purity was checked by                         
determinating absorption at a wawelenght of 230 and 280 nm, respectively. 
3.2.4 Agarose gel electrophoresis of DNA 
Agarose gels were used to separate nucleic acid molecules according to their size. 
Depending on the expected number of base pairs, gels containing                            
0.8% (w/v, >1000 bp) to 2.5% (w/v, >50 bp) agarose were prepared using 100 ml 0.5x 
TBE buffer. The suspension was heated until all the agarose was melted and 3 µl of 
ethidium bromide (10 mg/ml) was added. After cooling to approximately 60° C the 
gel was poured into the horizontal gel chamber. TBE buffer (0.5x) was used as the 
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electrophoresis buffer. Before loading the samples, 0.2 volumes of loading buffer 
were added and the sample was mixed. Electrophoresis was carried out at a steady 
voltage of 120-140 V. The size of the DNA fragments in the agarose gels was 
determined using appropriate size standards. DNA fragments were detected and 
analyzed by the Gel Doc XR gel documentation system (BioRad). 
 
5X TBE buffer 
450 mM      Tris base 
450 mM      Boric acid 
  20 mM      EDTA, pH 8.0 
 
 
6X Glycerol loading buffer 
10     mM    Tris/HCl, pH 7.5 
10     mM    EDTA, pH 8.0 
         30.00 %      Glycerol 
  0.01 %      bromophenol blue 
  0.01 %      xylene green 
 
3.2.5 Extraction of DNA fragments from agarose gels  
This method was used to extract and purify double-stranded DNA molecules of 70 bp 
to 10 kilo base pairs (kb) from low melting agarose gels. The principle of this method 
depends on the selective binding of DNA to silicagel membranes on QIAGEN spin 
columns. The kit was used according to the supplier’s instructions. 
3.2.6 TOPO cloning 
For the construction of specific real-time RT-PCR standards, PCR fragments were 
ligated into the TOPO cloning vector system (Invitrogen). The kit was used according 
to the manufacturer’s protocol. 
3.2.7 Transformation of E. coli 
Transformation of bacteria was done by gently mixing an aliquot of adequate 
competent bacterial cells (25-40 µl) with 1-2 µl of plasmid DNA or a ligation 
reaction. After incubation for 35 minutes on ice, bacteria were heat shocked for              
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30 seconds at 42° C and then immediately cooled down for 2 minutes on ice. After 
adding 600 µl of pre-warmed S. O. C. medium, bacteria were incubated at 37° C with 
shaking for 1 hour to allow recovery from the heat shock. They were then plated on 
LB-agar plates containing the appropriate antibiotic. 
3.2.8 Small-scale isolation of plasmid DNA 
Plasmids grown in mini-cultures (7 ml) over night were purified using the Qiagen 
Plasmid Mini Spin Kit according to the manufacturer’s instructions. 
3.2.9 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a very sensitive and powerful technique 
(Mullis. K.B. 1987; Saiki 1988) for the exponential amplification of specific DNA 
sequences in vitro by using sequence-specific synthetic oligonucleotides and               
a thermo-stable DNA-polymerase. The method was used for the amplification of 
genomic DNA for genotyping and in combination with reverse transcription of RNA 
for determination of mRNA expression levels of stretch-inducible gene products. 
3.2.9.1 Reverse transcription PCR (RT-PCR) 
To generate a representative cDNA pool from RNA templates 1-5 µg of total RNA 
were mixed with 1 µl of oligo (dT) 18 primer (10 pmol/µl) and RNase free water to     
a total volume of 14 µl. To facilitate hybrid formation of the oligo dT-primers with 
polyA-tails of mRNA, the mixture was heated to 70° C for 10 minutes and then 
quickly chilled on ice. After a brief centrifugation, the following was added to the 
mixture: 
4 µl of 5x First strand buffer 
1 µl of 0.1 M reverse transcriptase enzyme (RT) 
1 µl of 10 mM dNTPs 
The content of the tube was gently mixed and incubated at 42° C for 50 minutes for 
first strand cDNA synthesis. Then, the reaction was inactivated by incubating the 
mixture at 70° C for 10 minutes, and 180 µl of RNase-free water was added to dilute 
the resulting cDNA. These samples were used for the PCR reactions described below. 
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3.2.9.2 PCR amplification of DNA fragments 
Semi-quantitative PCR was performed by normalizing to the relative amount of 
cDNA of a house-keeping gene. For this purpose, glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) was chosen as an internal standard. The PCR reaction was 
performed in an automatic thermocycler (Biometra) programmed as shown in       
Table 13.  
 
Table 13: Program for semi-quantitative PCR  
PCR step Temperature ( in °C) Time 
Pre-denaturation 95° C 5 minutes 
Denaturation 95° C 30 seconds 
Annealing 56°- 60° C  (depending on the primers used) 40 seconds 
Extension 72° C 2 minutes 
Final extension 72° C 5 minutes 
 
 
3.2.9.3 Quantitative real-time PCR 
For quantitative analysis of changes in gene expression real-time RT-PCR analysis 
was used essentially as described in Wagner et al. (Wagner 2002). The plasmid 
standards for the gene products to be measured were cloned into pre-cut TOPO 
wectors (3.2.6) and the number of molecules / µl was calculated according to size (bp) 
and concentration. The number of plasmid templates used as standards varied between 
102 to 108 depending on the expected abundance of the gene product to be 
determined. As control gene products for the normalization of the cDNA amount 
added to the reaction, GAPDH and the endothelial cell marker PECAM-1/CD31 were 
used. Real-time PCR was carried out in a LightCycler instrument (Roche Diagnostics, 
Penzberg, Germany). The QuantiTect SYBR Green® kit (Qiagen) was used for the 
amplification reaction according to the manufacturer’s instructions. 
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3.2.10 Microarray analysis 
For the microarray analysis human endothelial cells were isolated from umbilical 
cords equal in length, age and growth characteristics. HUVEC were cultured on 
flexible membranes and only those that reached 90% confluence within 2 days were 
used for experiments. HUVEC were subjected to 10% cyclic stretch at a frequency of 
0.5 Hz for 6 hours (Chapter 3.1.4). Three independent experiments (static control plus 
stretched samples) were performed using cells from three unrelated individual 
umbilical cords. High quality mRNA was isolated as described, tested by real time 
RT-PCR, aliquoted and stored at -80° C. Similarly, mouse SMC derived from wild 
type and zyxin-deficient mice were seeded on Flexercell plates and subjected to cyclic 
stretch as described above. Again, total RNA was isolated, tested for quality and 
stored at -80° C in aliquots. Fifteen µl (corresponding to 5-10 µg total RNA) of each 
sample were delivered for microarray analysis.  
Further, Affymetrix GeneChip expression measures (Cope 2004) were performed by 
microarray-team, Mannheim (Prof. Dr. Norbert Gretz, Walter Bosbach, Li Li, 
Priyanka Shahi, Susanne Böhn; University Clinics of Mannheim). Hybridization and 
processing of the genome wide array HG-U133A chips (human) and the genome wide 
array chips, MG-430 2.0 (mouse) were performed according to the standard protocols 
available from Affymetrix (Santa Clara, CA, USA). Detailed information about the 
analytical settings and conditions are available on http://www.ma.uni-
heidelberg.de/inst/zmf/affymetrix/ablauf_e.html. Raw microarray data from 
Affymetrix CEL files were normalized using the method of Huber et al. (Affymetrix 
Microarray Suite methods in comparative studies, http://affycomp.biostat.jhsph.edu). 
Analysis of variance (ANOVA) was performed using the SAS software package 
MicroArray Solutions version 1.3 (SAS Institute Inc. 2004; http://www.ma.uni-
heidelberg.de/inst/zmf/affymetrix/datenanalyse_e.html). Gene annotation was 
obtained through the Affymetrix NetAffx index 
(http://www.affymetrix.com/analysis/index.affx). Besides the simple analysis of 
single differentially expressed gene products, pathways of gene products functionally 
linked to each other were characterized to facilitate interpretation of the bulk of data. 
To define significantly affected pathways, two approaches were used; first, an over-
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representation (ORA) approach using Fisher’s exact test as described by Draghici et 
al. (2003), and second a functional class scoring (FCS) approach using a modified 
Gene Set Enrichment Analysis (GSEA, http://www.broad.mit.edu/gsea) as described 
by Subramanian et al. (2005) and Mootha and Lindgren et al. (2003) was used as 
implemented in the Bioconductor Package Global Test 3.0.4.  A total number of 327 
pathways generated from the KEGG database (Kyoto Encyclopedia of Genes and 
Genomes, http://www.genome.ad.jp/kegg/pathway.html), Gene Ontology (GO) 
annotations (Consortium 2000), and the module map for cancer compiled by Segal et 
al. (2004), were taken for analysis using the Bioconductor Annotation Package 
hgu95av2 1.8.4 (Kanehisa 2000, 2008; Manoli 2006). The overall number of 
significantly/non-significantly differentially expressed genes per chip was cross-
tabulated against the number of significantly/non-significantly expressed genes of a 
pathway (Kenzelmann 2007), with a P- value < 0.001 judged to be significant. 
3.3 Protein chemistry 
3.3.1 Isolation of total cellular protein 
Proteins were extracted from freshly harvested or frozen cells by homogenization in 
hypotonic protein lysis buffer (Table 14). Lysates were incubated on ice for 30 
minutes and centrifuged at 3000 rpm for 5 minutes at 4°C. The supernatant, 
containing cellular membranes, organelles and cytosolic proteins, was collected and 
stored at –80° C or used immediately for Western blot analysis (3.3.6). 
Samples for protein analysis by two-dimensional (2-D) gel electrophoresis were 
prepared using chaotropic and reducing agents (Link 1999; Rabilloud 1999).           
For harvesting of the cells, they were collected with a cell scraper (Sarstedt Inc.) in 1 
ml of PBS and transferred into a microcentrifuge tube and centrifuged at 3000 rpm for 
3 minutes. The pellet was resuspended in 250 µl of the strongly chaotropic 2-D 
sample buffer (Table 14) and thoroughly mixed several times for 15 minutes to sheer 
genomic DNA and dissolve all proteins. The lysates were then centrifuged for 3 
minutes at room temperature to sediment insoluble components and the supernatants 
were stored at –80° C until analysis. 
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Table 14: Components of protein lysis buffer and chaotropic buffer 
Protein lysis buffer Chaotropic 2D sample buffer 
10 mM KCl 7 M urea 
0.1mM EDTA 2 M thiourea 
0.1mM EGTA 4% CHAPS 
10 mM Hepes 50 mM DTT 
1% Triton X-100 0.2% Bio-Lyte 3/10 ampholyte 
2 mM DTT 0.2% phosphatase inhibitors 
50 µM Pefablock.  
25µM protease inhibitors  
 
 
3.3.2 Protein dephosphorylation 
For the dephosphorylation of zyxin, total non-denatured cell lysates were used. The 
Mn2+-dependent protein phosphatase 1 (PP1) was chosen for its broad substrate 
spectrum including some activity towards phosphotyrosine residues. The reaction was 
performed in PP1 buffer (100 mM NaCl, 50 mM Hepes, 0.1 mM EGTA, 2 mM DTT, 
0.025% Tween 20, pH 7.5) supplemented with 1 mM MnCl2 with 0.5 units of PP1 at 
30°C for 90 minutes in a total volume of 20 µl. After adding 10 volumes of chaotropic 
lysis buffer (Table 14) and protein solubilisation, PP1-mediated dephosphorylation 
was further analyzed by standard 2-D gel electrophoresis procedure followed by 
Western blot as described below.  
3.3.3 Enrichment of nuclear protein 
For enrichment of the nuclear protein fraction from cultured cells for 2-D gel 
electrophoresis, the ReadyPrep protein extraction kit (BioRad) was used according to 
the manufacturer’s protocol. The nuclear pellet was then solubilised in sample buffer 
(Table 14) and used for 2-D gel electrophoresis. 
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3.3.4 Determination of protein concentration 
To determine protein concentration, the colorimetric Bradford protein assay (Bradford 
1976) was employed. This is a dye-binding assay based on the differential colour 
change of Coomassie Brilliant blue G dye in response to various concentrations of 
protein. As an external standard, the bovine serum albumin (BSA; stock solution of    
1 mg/ml) was diluted in order to obtain standard dilutions in the range of                    
10 - 100 µg/ml. The Bradford reagent was diluted in 1:5 ratios with deionised water. 
In a 96-well plate, 80 µl of each standard used and the samples (diluted 1:100) were 
mixed with 200 µl of the diluted Bradford reagent. Optical density of the color 
reaction was measured at 595 nm in a microplate reader (PowerWave XS universal 
microplate reader, BIOTEK Instruments) and the standard was used to generate a 
calibration curve. 
 
3.3.5 Sodium Dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
For the separation of proteins exclusively on the base of their size, SDS-PAGE was 
used. For the preparation of the gels the solutions described in Table 15 were freshly 
prepared. SDS-polyacrylamide gels were made according to the Laemmli method 
(Laemmli 1977). Gels from 10 – 12% were poured between the glass plates 
depending on the size of the proteins to be separated and overlaid after polymerization 
with a 4% stacking gel. Proteins were denatured by the addition of 4x sample loading 
buffer and heated for 5 minutes at 95° C. Thereafter, proteins were separated by 
electrophoresis at fixed voltages of 100 V for the stacking gel, and 200 V through the 
separating gel. 
 
Tris-glycine-SDS running buffer (1X) 
  25.0 mM     Tris HCl, pH 8.3 
192.0 mM     Glycine 
    0.1%         SDS 
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Loading Buffer (4X) 
150.0 mM     Tris HCl, pH 6.8  
300.0 mM     DTT  
    6.0%         SDS 
    0.3%         Bromophenol blue  
  30%            Glycerol  
 
 
Table 15: Formulations for SDS-PAGE separating and stacking gels 
 Separating gel 10% Separating gel 12% Stacking gel 4% 
Acrylamide stock (30%) 3.3 ml 4.0 ml 0.65 ml 
1.5 M  Tris HCl, pH 8.8 2.5 ml 2.5 ml - 
0.5 M  Tris HCl, pH 6.8 - - 1.25 ml 
            dd H
2
O 4.1 ml 3.35 ml 3.05 ml 
20%   SDS 50 µl 50 µl 50 µl 
10%   APS 50 µl 50 µl 25 µl 
            TEMED 10 µl 10 µl 10 µl 
 
3.3.6 Western blot analysis 
After separation by SDS-PAGE (3.5.4), proteins were transferred onto a pre-hydrated 
(5 minutes in 100% methanol and 45 minutes in ddH2O) PVDF membrane at 350 mA 
for 45 minutes in the transfer buffer. The membrane was then dried for 2 hours at 
50°C or directly blocked for at least 2 hours with blocking buffer. 
The primary antibody (Table 6, diluted 1:1000 to 1:10000 in washing buffer) was 
added to the membrane and incubated at ambient temperature for 2 hours. Thereafter              
the membrane was washed 3 times for 10 minutes with washing buffer. The 
appropriate secondary antibody conjugated to horseradish peroxidase (Table 5; 
1:10000) was added and the membrane was further incubated at ambient temperature 
for 1 hour. After 1 hour, the membrane was washed 3 times for 10 minutes in washing 
buffer. 
The complex of proteins with primary and secondary antibodies was detected by 
using ECL solution (Amersham Pharmacia Biotech, Freiburg, Germany), according to 
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the manufacturer’s instructions. The light generated by the enzymatic reaction was 
detected in a ChemiDoc chamber (BioRad) 
Transfer buffer 
25.0     mM    Tris 
19.2     mM    Glycine  
20%               Methanol  
 
Washing Buffer 
Triton X-100  2.5 g  
PBS 1X          1.0 L  
 
Blocking Buffer 
Milk powder 2.5 g per 50 ml of washing buffer 
 
3.3.7 Two-dimensional gel electrophoresis 
The analysis of complex protein mixtures and protein modifications was performed 
by using the Protean IEF System (BioRad Laboratories) for the first dimension and 
the Protean II xi cell system (BioRad Laboratories) for the second dimension protein 
separations. 2D gel elecrophoresis was established according to the protocol described 
by O’Farrell (O'Farrell 1975) with minor modifications (see below). 
3.3.7.1 Isoelectric focusing (IEF) 
During the first dimension proteins are trapped at their respective isoelectric point 
(pI), the pH at which a given protein has no net charge and hence does not migrate in 
an electric field. ReadyStrip IPG Strips pH 3-10 (length 17 cm; BioRad) were used 
following the instructions provided. Each sample was diluted in rehydration buffer (to 
the total volume of 300 µl and maximal protein concentration of 20 mg/ml) and 
applied directly into the focusing tray to allow uniform absorption in the course of 
rehydration of the strip. The loaded strip was then covered with mineral oil to prevent 
fluid evaporation during the next steps and mounted into the Protean IEF focusing 
tray (BioRad). Rehydration was run under static conditions for 19 hours at 20°C. 
Thereafter, isoelectric focusing was performed according to the optimized program 
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(for detailed conditions see Table 16). IEF was run with a current of 50 µA per strip 
for about 19 hours at 20°C until no current was measureable.  
 
Table 16: Focusing conditions for 17 cm ReadyStrip, pH 3-10 
End voltage Volt  per hours Ramp 
10.000 V 60.000 V x hour rapid 
 
Table 17: Equalibration and rehydration buffers used for 2-D gel  
electrophoresis analysis 
Rehydration buffer Equalibration buffer I Equalibration buffer II 
   
  7    M urea 
  2    M thiourea 
  4% (w/v) CHAPS 
50 mM DTT 
0.2% 100x Bio-Lyte 3/10 ampholyte 
0.2%  protease inhibitor 
  
  6         M urea 
  0.375  M Tris HCl, pH 8.8 
  2%           SDS 
20%           glycerol 
  2% (w/v) DTT 
 
  
  6        M  urea 
  0.375 M Tris HCl, pH 8.8 
  2%          SDS 
20%          glycerol 
 
 
3.3.7.2 Equilibration and SDS-PAGE 
Before proceeding with the second dimension, IEF strips were equilibrated in SDS-
containing equilibration buffers I and II (Table 17) for 10 minutes each followed by 
rinsing with 1X Tris-glycine-SDS running buffer. 
For SDS-PAGE, 12% separating gels were prepared according to the standard 
protocol described above (Laemmli 1970). After full polymerization (over night) 
equilibrated IEF stripes were mounted onto the separating gel and fixed with 1% 
agarose. SDS-PAGE electrophoresis was run in 1X Tris-glycine-SDS running buffer 
(3.3.5) at a current of 16 mA per gel for 30 minutes, then at 24 mA per gel for another 
5 hours. The Kaleidoscope Precision Plus Protein Standard (BioRad Laboratories) 
was used to monitor the progress of the run. After electrophoresis, proteins were 
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transferred onto PVDF membranes. Zyxin was detected by using the B72 antiserum 
as described (3.3.6). 
3.4 Enzyme-linked immunosorbent assay (ELISA) 
Pre-coated enzyme-linked immunosorbent assay (ELISA) was used for quantitative 
determination of interleukin-8 (IL-8), endothelin-1 (ET-1) and atrial natiuretic peptide 
(ANP) concentrations in cell culture supernatants. All samples were thawed only once 
at the time of testing and analyzed according to the procedures provided by the 
manufacturers. 
3.5 Immunofluorescence analysis 
3.5.1 Cell fixation 
Human cells, grown on glass cover slips or BioFlex membranes, were routinely fixed 
by using one of the fixation techniques described below. 
For solvent fixation and study of the localisation of zyxin, cells were fixed with        
50% methanol/50% acetone (1 ml was added and incubated further for 20 minutes at 
−20°C in the dark). The cover slips were allowed to air dry for 2 hours and re-
hydrated with PBS. For observation of actin filaments and distribution of ANP in 
HUVEC, paraformaldehyde fixation was performed. First, after the medium was 
aspirated and cells were washed with PBS, 1 ml of PBS containing 4% formaldehyde 
was added into each well and incubated for 10 minutes at 4oC in the dark. Thereafter, 
cells were quenched with 50 mM ammonium chloride in PBS and membranes were 
permeabilized by 0.1% Triton X-100 in PBS at room temperature for 10 minutes. 
3.5.2 Immunostaining of fixed cells 
After fixation the cover slips were placed upside in a 6-well plate, covered with 
blocking buffer (10% goat serum in 0.1% Triton/PBS, pH 7.4) at ambient temperature 
for 30 minutes. Cover slips were then placed downside on paraffin plastic toil with the 
primary antibody diluted in blocking buffer (20 µl) for 2 hours at room temperature, 
washed in PBS, and finally exposed upside to the fluorescent dye-conjugated 
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secondary antibody labelled with Alexa 488 or Alexa 594 in blocking buffer (1 hour 
at room temperature). Following this incubation, 3 washing steps with PBS were 
performed before post-fixation by using 50 mM acetic acid in ethanol. The coverslip 
was then mounted onto a large coverslip with 6-20 µl of 50% glycerine in PBS and 
sealed with nail polish. Mounted slides were then analysed using the image system 
(Olympus) equipped with the MetaMorph analysis software. Primary and secondary 
antibodies used are listed in Tables 5 and 6 (Chapter 2.4). 
 
Blocking buffer 
10%      goat serum (Sigma Aldrich) 
 0.1%    Triton in PBS, pH 7.4 
 
3.6 Immunohistochemistry 
3.6.1 Tissue preparation for paraffin embedding 
The freshly prepared tissues were fixed in zinc fixative solution for 24 hours to 
prevent alterations in the cellular structure. The dehydration process was 
accomplished by passing the tissue through a series of increasing ethanol 
concentrations. For this purpose, the tissue was placed in 70%, 80% and 96% ethanol 
for at least 1 hour at ambient temperature. Later, the ethanol was removed from the 
tissue by incubating it 1 hour in isopropanol. Finally, the tissue was embedded in 
melted paraffin (Sigma Aldrich) and incubated at 60° C overnight. The day after, 
paraffin with the tissue was poured into the metal mould to form a block. The block 
was allowed to cool and was consecutively processed for sectioning or stored at room 
temperature. The paraffin sections (5 µm thick) were dried at 40° C overnight and 
then processed further for immunohistological analyses. 
 
Zinc fixative solution 
  0.1    M    Tris HCl, pH 7.4 
  3.2 mM    Ca(CH3COO)2 X H2O 
22.8 mM    Zn(O2CCH3)2(H2O)2 
35.9 mM    ZnCl2 
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3.6.2 Haematoxylin staining of paraffin sections 
The stored slides with the paraffin sections were first incubated three times in Xylol 
for 5 minutes, followed by consecutive incubations in 99%, 85% and 70% ethanol for 
5 minutes each. Slides were then washed 5 minutes in ddH2O and placed for                  
5 minutes in 0.1X Mayer´s haematoxylin solution (Sigma Aldrich). Staining was 
terminated by washing in running tap water for 10 minutes. Thereafter slides were 
incubated in ddH2O for 1 minute followed by 70%, 85% and 96% ethanol and two 
times in Xylol for 5 minutes each. Finally, the stained tissues were sealed using 
DePeX mounting medium and analysed by convential light microscopy. 
 
3.7 Perfusion of isolated murine femoral arteries 
Freshly isolated femoral arteries isolated from wild type C57BL/6J or C57BL/6J 
zyxin (-/-) null mice were subjected to defined perfusion conditions by using a 
Pressure Myograph System Model 110P (Danish Myo Technology, Copenhagen, 
Denmark). 
Perfusion buffer (Table 19) was freshly prepared at the day of the experiment by 
dropwise addition of 25X solution II to 800 ml water plus 40 ml solution I under 
stirring (for details see Table 18). Thereafter, the buffer was adjusted to one liter with 
ddH20 and saturated with carbon dioxide and oxygen (95% O2, 5% CO2) for 20 
minutes. Partial O2 pressure was maintained at a value of 160 mmHg, PCO2 at a value 
of 37 mmHg, pH was equilibrated to 7.4 and the solution was completed by adding 
EDTA (260 µl/l) and D-glucose (2 g/l). Buffer samples (0.5 ml) were taken at various 
time points for control of pH and PO2/PCO2 using a blood gas analyser (Radiometer, 
Kopenhagen, Denmark). 
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Table 19: Perfusion buffer pH 7.4 (1X) 
Solution I Solution II 
Chemical Concentration (mmol/l) Chemical Concentration (mmol/l) 
NaCl               119.00 NaHCO3   2.10 
CaCl2  1.25 KH2PO4   1.18 
KCl 4.70   
MgSO4 x 7 H2O   1.17   
 
Table 18: Perfusion buffer pH 7.4 (25X) 
Solution I Solution II 
Chemical Concentration (g/l) Chemical Concentration (g/l) 
NaCl            173.850 NaHCO3             52.10  
CaCl2  5.875 KH2PO4 4.08 
KCl  8.760   
MgSO4 x 7 H2O  7.390   
 
For the isolation of the femoral arteries, animals were euthanized in CO2 chambers. 
The excised leg was placed in a Petri dish with equilibrated perfusion buffer.   The 
femoral artery was first separated from the accompanying vein and dissected from 
connective tissue. Segments of the femoral artery (0.5 - 1 cm) were cut from the distal 
and proximal end to be investigated. Artery segments were mounted on glass 
capillaries and inserted into the myograph system (Figure 3.2), which was modified 
for the investigation of smaller vessels (diameter ~120 µm).  
 
 
 
 
 
 
 
Figure 3.2: The in situ perfusion model of the femoral arteries. 
    femoral artery 
INFLOW OUTFLOW 
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The glass capillaries used for perfusion experiments were fabricated using a P-87 
Flaming/Brown micropipette puller (Sutter Instrument Company, Novato, USA). To 
achieve a final tip-diameter of 120 µm, capillaries were pulled from 0.15 mm glass 
cannulas (GB150-8P, Science products GmbH, Hofheim, Germany) with the program 
optimized according to an operation manual provided by the manufacturer’s of the 
puller. Thereafter, the capillaries were cut to the appropriate length (approximately 
1.5 cm). 
Buffer temperature was kept at 37°C. The mounted vessel was gradually pressurized 
at 10-30 mmHg over a period of about 15 minutes. After that the vessel was 
equilibrated at an intraluminal pressure of 20 mmHg for 1 hour. The vessel chamber 
was continuously refilled with pre-heated (37°C) and equilibrated perfusion buffer. 
A pressure transducer set in line with the femoral artery together with the MyoView™ 
interface allowed continuous application and control of temperature and pressure. 
Analysis of changes in the diameter of the vessel was obtained by using the 
MyoView™ software, processing the video microscope real time image of the vessel, 
and was calculated automatically according to the adjusted calibration. 
3.7.1 In situ studies of endothelium-dependent relaxation 
The pressure myograph allows to quantitatatively determine the response of 
pressurised femoral arteries to vasoactive substances. The response of the arteries 
cannulated in the system was recorded as changes in luminal diameter. Baseline 
measurements were obtained at 3 points of the experiment: once freshly after isolation 
(passive diameter), than after 1 hour pressurising at 60 mmHg, when static conditions 
with constant flow were achieved (diameter measured under physiological 
conditions). Thirdly data were obtained from arterial segments pre-constricted with 
phenylephrine (0,1 µmol/L) with an intraluminal pressure set at 60 mmHg. Artery 
segments were allowed to equilibrate for one hour before being pre-constricted to 40 - 
60% of their resting diameter with 1 µmol/L phenylephrine for subsequent relaxation 
studies. Pre-constricted vessels were studied for dilator responses by giving 
cumulative doses of acetylcholine (end concentrations of 10 nmol/L – 10 µmol/L), to 
the bath. Changes in vessel diameter were monitored as described. Contraction in 
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response to phenylephrine was measured as change in diameter caused by 0,1 µmol/L 
phenylephrine. Relaxation in response to acetylocholine was expressed as gradual 
increase in diameter caused by different agonist concentrations in every vessel. 
Results were presented as the percentage of relative changes in vessel diameter. 
The functional and cellular integrity of the segments was routinely checked by 
immunohistochemical staining for the endothelial cell marker CD31. 
3.8 DOCA-salt model of hypertension and telemetric blood pressure 
measurement 
Before induction DOCA-salt hypertension in mice, they were unilaterally 
nephrectomized and implanted with the telemetric catheter. After 6 days, a DOCA 
pellet (50 mg DOCA, 21 days release time, Innovative Research of America) was 
implanted subcutaneously, and additionally drinking water was supplemented with 
1% (w/v) NaCl. In two performed experiments, wild-type and zyxin-/- mice were 
subjected to the same treatment. Thereafter the blood pressure was monitored using a 
radiotelemetry system (PA-C10, Data Sciences International) in conscious, 
unrestrained mice, as described by Mills et al. (Mills 2000).  
3.9 Statistical analysis 
For statistical analysis the InStat software version 3.0 (GraphPad Inc., San Diego, 
USA) was used. Data are presented as means ±SEM. In all cases, P-values < 0.05 
were considered as statistically significant. When comparing more than two groups, 
ANOVA was used, as was appropriate. For statistical procedures concerning the 
microarray analyses see 3.2.10. 
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4. Results 
4.1 Mechanism of wall tension-induced zyxin activation in human 
cells 
This part of the thesis was conducted at the cellular level with emphasis on human 
primary cultured endothelial cells. In order to mimic supra-physiological wall tension, 
cells were exposed to cyclic stretch using a well-characterized in vitro model,           
the Flexercell strain unit (Shrinsky 1989; Cattaruzza 2004; Kakisis 2004; Lacolley 
2004). 
4.1.1 Effect of cyclic stretch on the cellular localisation of zyxin 
HUVEC grown on flexible elastomers respond with a rapid remodelling of their actin 
cytoskeleton if exposed to cyclic stretch. In order to localize zyxin, 
immunofluorescence analysis of endothelial cells using the zyxin specific antserum 
B71 was performed. 
The analysis showed that under static conditions zyxin was mostly located in focal 
adhesion points (Figure 4.1 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Immunofluorescence analysis of zyxin localization in HUVEC. Human umbilical 
vein endothelial cells grown on collagen-coated BioFlex plates were subjected to cyclic stretch 
(10% elongation, 0.5 Hz, 6 hours). Zyxin was detected by the specific B71 antiserum. 
Immunofluorescent staining of zyxin revealed a pediment localisation of zyxin in focal 
adhesions (FA). Cyclic stretch, however, causes a translocation to stress fibres (SF) and the 
nucleus (Nu; panel B). Focal adhesions, however, remain intact in this process as analyzed by 
staining for vinculin, another component of FA (not shown). 
(B) 
static 
(A) 
   10% cyclic stretch 
FA 
Nu 
SF 
FA 
FA 
                            25µm 
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Upon exposure to cyclic stretch (10% elongation, 0.5 Hz, 6 hours), zyxin was released 
from focal adhesions and accumulated in stress fibres and the nucleus, as shown in 
Figure 4.1 B, right panel. 
To evaluate the kinetics of zyxin translocation in more detail, cells were exposed to 
cyclic stretch as described before (10% elongation, 0.5 Hz) but fixed at different time 
points (after 30 to 360 minutes). Immunofluorescence analysis revealed that zyxin not 
only relocates, but shuttles between focal adhesions, stress fibers and the nucleus of 
endothelial cells until, after 6 hours, the protein is stably located in the nucleus 
(analyses for up to 18 hours are not shown). Zyxin relocated to stress fibers and the 
nucleus already in the early phases of mechanical overload, i.e. after 30 to 60 minutes 
(Figure 4.2).  
Within 90 minutes, zyxin accumulated at high density in nuclear compartments of the 
endothelial cells and then dissociated back to the focal adhesions at around 120 
minutes. After this relocation, zyxin was redistributed to the nucleus at about 240 
minutes and remained there for up to 18 hours (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Time course of stretch-activated zyxin translocation. One of 6 representative 
immunofluorescence analyses of zyxin shuttling between focal adhesions, stress fibers and the 
nucleus in HUVEC exposed up to 6 hours to cyclic stretch (10% elongation, 0.5 Hz). 
Although the time course of translocation varies in a range of several minutes, the 
characteristic biphasic kinetics could be observed in all experiments. 
30‘ 60‘ 90‘ 
360‘+ 240‘ 120‘ 
                            50µm 
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4.1.2 Effect of ET-1 and ANP on zyxin activation 
To analyse whether - as in atrial myocytes – ET-1 and ANP mediate wall tension-
induced signalling also in endothelial cells, we applied ANP (10 and 1 nM) to the 
cultured HUVEC for 6 hours. ANP (1 nM) in fact stimulated zyxin translocation from 
focal adhesions to the nucleus (Figure 4.3), suggesting that is a surrogate stimulus for 
wall tension. 
To assess the role of ET-1 in ANP-induced zyxin activation, the cells were exposed to  
ET-1 (10 nM) with or without the ETB receptor-selective antagonist BQ788 (1 µM) in 
the presence or absence of cyclic stretch and/or ANP (1 nM). Immunofluorescence 
detection of zyxin demonstrated that in cells exposed to cyclic stretch ETB receptor 
activity was crucial for zyxin translocation to the nucleus (Figure 4.4, panel A-III). 
However, in cells additionally exposed to ANP, BQ788 had no effect on zyxin 
translocation (Figure 4.4, panel A-IV), suggesting that ET-1-induced ETB-R 
activation occurs upstream of the ANP-mediated effects. 
To further demonstrate that ET-1-induced ETB-R activation mediates ANP release 
and consecutively zyxin translocation to the nucleus, static cells were exposed to       
ET-1 (10 nM) with or without BQ788 (1 µM). Under static conditions, ET-1 alone in 
fact triggered zyxin translocation further supporting the hypothesis that ET-1 
facilitates ANP felease from endothelial cells (Figure 4.4, panel C-II) similar to the 
situation in the atria of the heart. 
 
 
 
 
 
 
 
 
 
Figure 4.3: Effects of ANP on the cellular localisation of zyxin in cultured HUVEC. 
Exemplary analysis of zyxin relocation to the nucleus. HUVEC were preincubated as outlined in 
Materials and Methods (section 3.1.5). ANP (1 nM) activates the nuclear translocation of zyxin 
also in quiescent cells (B). 
(B) 
control ANP (1 nM) 
(A) 
          50µm 
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Figure 4.4: Effects of ANP and ET-1 on the cellular localisation of zyxin in cultured 
HUVEC. HUVEC were preincubated as outlined in Materials and Methods (section 3.1.5). 
(A) Pretreatment with ANP (1 nM) elicts nuclear translocation of zyxin in quiescent cells   
(A-II). The ETB-R-specific antagonist BQ788 inhibits stretch-induced zyxin translocation to 
the nucleus (A-III). However, BQ788 does not affect ANP-mediated effects in these cells    
(A-IV). (B) ET-1 alone also stimulates zyxin translocation in quiescent endothelial cells      
(B-II). This effect is ETB-R-dependent (B-III). 
 
4.1.3. Effects of cyclic stretch on functional natriuretic peptide gene 
expression 
After it was evident that ANP mediates stretch-induced zyxin translocation to the 
nucleus of human endothelial cells, the effect of cyclic stretch on the expression of all 
types of natriuretic peptides, ANP, BNP and CNP, was examined next. In line with 
previous reports (Cai 1993), human umbilical vein endothelial cells express all 
natriuretic peptides (Figure 4.5). Interestingly, however, prolonged exposure to cyclic 
stretch (6 hours, 10% elongation, 0.5 Hz) had diverse consequences on the expression 
of the three genes. As shown in Figure 4.5, cyclic stretch stimulated both CNP          
(panel A) and ANP (panel C) gene expression, but had no effect on BNP (panel B). 
I II III IV 
static 
cyclic 
stretch 
BQ788 (1 µM)  ANP + BQ788 ANP (1 nM) control 
(A) 
ET-1 + BQ788 BQ788 (1 µM) ET-1 (10 nM) control 
I II III IV 
static 
(B) 
            50µm 
        50µm 
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It has been demonstrated previously that expression of ANP is controled by ET-1 in 
atrial myocytes. Similarly, the effects of ET-1 and its B-type receptor on ANP gene 
expression in HUVEC were analyzed. ANP up-regulation was abolished in HUVEC 
exposed to cyclic stretch, when the ETB-R was blocked by using the specific inhibitor 
BQ788 (Figure 4.5, panel C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Quantitative real-time PCR analysis of CNP (A), BNP (B) and ANP (C) gene 
expression in HUVEC. (A) CNP mRNA expression is 2-fold increased upon exposure to 
cyclic stretch, whereas BNP mRNA expression in these cells was not affected (B). (C) ANP 
mRNA expression is up-regulated upon cyclic stretch in an ETB-R dependent manner.                
*P < 0.02 vs. static control; #P<0.05 vs. stretched cells; number of individual experiments as 
indicated. 
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       2 
(2 - 0.2 n) Creal = x Cmeasured 
4.1.4 Wall tension-induced ANP and ET-1 release  
In atria, wall tension-induced release of ANP is mediated by ET-1 secreted by 
endothelial cells. To analyse whether endothelial cell ANP release is similarly 
regulated supernatants were collected from cultured HUVEC exposed to cyclic stretch 
for 0 to 360 minutes an equal volume of fresh media was replaced each time. 
Concentrations of ET-1 and ANP were measured by ELISA and calculated taking into 
account the serial dilutions as follows: 
 
Upon static conditions, the cells produced very low amounts of ANP                        
(0.1-0.12 nmol/L). Cyclic stretch rapidly elevated the ANP concentration in 
supernatant to 3.6 nmol/L after 1 minute and then again after 60 and 360 minutes, 
although to a much lesser extent (Figure 4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Quantitative analysis of ANP concentration in HUVEC supernatants by 
ELISA. ANP release from endothelial cells upon exposure to cyclic stretch (10% elongation, 
0.5 Hz) at different time points. *P< 0.05 vs. static control; #P<0.05 as indicated; n=4. 
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After 360 minutes, appeared to reach a plateau 2 to 3-fold above the basal level (not 
shown). In another series of experiments, BQ788 at a final concentration of 1 µmol/L 
was added to the cells 6 hours before application of cyclic stretch. Under these 
conditions, cyclic stretch did not lead to an increase in ANP release (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Quantitative analysis of ANP concentration in HUVEC supernatants by 
ELISA. BQ788 was able to completely suppress ANP secretion from these cells after 360 
minutes. *P< 0.05 vs. static control; ##P<0.01 vs. 360 minutes of stretch; n=4. 
 
 
Figure 4.8 shows the release of ET-1 upon exposure to cyclic stretch into the 
conditioned medium of the cultured HUVEC. In this series of experiments, exposure 
to cyclic stretch for 30 to 360 minutes resulted in an increased ET-1 release, which 
appeared to reach a plateau beyond 360 minutes (not shown). Like ANP, the kinetics 
of ET-1 release seems to match those of zyxin translocating to the nucleus. 
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Figure 4.8: Quantitative analysis of endothelin-1 concentration in HUVEC supernatants by 
ELISA. *P<0.05 vs. static control; #P<0.05 vs. corresponding control; n=4. 
 
 
 
Taken together, these data suggest that ET-1 mediates ANP secretion from HUVEC 
in response to cyclic stretch. 
 
4.1.5 Analysis of natriuretic peptide receptors expression in HUVEC 
In endothelial cells, ANP acts via activation of the natriuretic peptide receptor type A, 
to which it has a high affinity. The C-type receptor, although principally coupled to 
several trimeric G-proteins, is regarded to be a scavenger receptor, its downstream 
signalling pathway is not yet known. In respect to these facts, expression of both 
natriuretic peptide receptors was determined by real-time PCR in cultured HUVEC. 
These analyses suggest indicated that NPR-A as well as NPR-C is expressed in 
HUVEC under static conditions, while an increase in cyclic stretch had no effect on 
the expression level of these receptors (Figure 4.9). Expression of NPR-B, however, 
was very low (data not shown). 
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Figure: 4.9: Real-time PCR analysis of NPR-A (A) and NPR-C (B) gene expression in 
HUVEC. Both ANP-specific natriuretc peptide receptors are expressed in the endothelial 
cells. Basal mRNA expression, however, does not change in response to 6 hours of cyclic 
stretch did not alter the expression; n = 4. 
 
 
 
 
 
 
To confirm the constitutive expression of both types of receptor, additional 
immunofluorescence analyses using NPR-A and NPR-C antibodies were preformed. 
Similar to previous findings, HUVEC stained uniformly positive for either ANP 
receptor under both static conditions and in response to cyclic stretch (6 hours,               
10% elongation, 0.5 Hz) without any apparent changes in expression or localisation 
(Figure 4.10). Whereas NPR-C seems to be localized mostly in a peri-nuclear 
vesicular compartment, NPR-A predominantly shows a diffuse staining typical for 
non-clustered cell surface receptors. 
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Figure 4.10: Immunofluorescence analysis of NPR-A and NPR-C localization in 
HUVEC. Both ANP receptors were visualized by immunofluorescence staining using 
antibodies against NPR-A (panel B) and NPR-C (panel A) counterstained with Alexa 
green secondary antibodies. Analysis reveals that both natriuretic peptide receptors are 
equally distributed under both static and stretch conditions. 
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4.1.6 Determination of the signalling pathway of ANP-mediated zyxin 
activation 
Protein kinase G (PKG), the principal effector kinase activated by cGMP in the 
cardiovascular system, provides the main signal downstream of ANP. In this context, 
zyxin localisation in static or stretched HUVEC treated with a potent inhibitor of PKG 
signalling, Rp8pGPT-cGMPS (100 µM), was investigated next by way of 
immunofluorescence analysis. As shown in Figure 4.11 panel B, PKG activity in fact 
seems crucial for the nuclear translocation of zyxin, pointing towards its involvement 
in stretch-induced zyxin activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Determination of the role of protein kinase G (PKG) signalling in nuclear 
translocation of zyxin in cultured endothelial cells. HUVEC were stretched (6 hours,              
10% elongation, 0.5 Hz). Nuclear translocation of zyxin (A) but not to stress fibers was 
effectively inhibited by the specific PKG-inhibitor Rp8pGPT-cGMPS (B). In contrast, the NO 
donor DETA-NONOate elicted nuclear translocation of zyxin already in static cells (C). 
Representative immunofluorescence analyses. 
 
 
 
Endothelial cells produce large amounts of nitric oxide (NO) also leading to high 
levels of cGMP through activation of soluble guanylate cyclase (sGC; (Denninger 
1999; Hamad 2003; Münzel 2003). To analyze whether NO-induced cGMP 
generation also mediates the extended accumulation of zyxin in the nucleus, DETA-
NONOate – a NO donor with slow release kinetics – was added to the cell medium to 
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simulate continuous production of NO. The NO donor in fact provoked nuclear 
translocation of zyxin already in static cells, further supporting the pivoral role of 
PKG therein. However, in stretched endothelial cells accumulation of zyxin in the 
nucleus appeared to be less prominent (Figure 4.11, panel C).  
 
4.1.7 Analysis of zyxin phosphorylation 
To analyse the presumably PKG-mediated phosphorylation of zyxin, 2D-gel 
electrophoresis followed by Western blot analysis with an antiserum specific for 
zyxin (B72) was used. For translocation of zyxin the endothelial cells were either 
subjected to 6 hours of cyclic stretch (10% elongation, 0.5 Hz) or exposed to ANP           
(1 nM). Either total cell lysates or nuclear extracts were analyzed. As shown in Figure 
4.12 two isoforms of zyxin with different pI values (6.76 and 7.0, respectively) could 
be identified. These changes in pI strongly point towards the formation of a 
phosphorylated variant of zyxin in response to stretch (Figure 4.12) or ANP             
(Figure 4.13). To verify that indeed phosphorylation causes this shift in pI the total 
endothelial protein lysates were pre-incubated with protein phosphatase 1 (PP1) prior 
to Western blot analysis. This treatment completely eliminated the more acidic protein 
spot corrobarating that zyxin is in fact phosphorylated in response to cyclic stretch or 
ANP (Figure 4.14).  
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Analysis of zyxin phosphorylation in the cultured HUVEC under static 
conditions and in response to cyclic stretch. Representative Western blot analyses of total 
protein lysates after 2D-gel electrophoresis. Zyxin was detected by using the B72 antibody. 
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Figure 4.13: Analysis of zyxin phosphorylation in the cultured HUVEC under static 
conditions and exposed to ANP (1 nM). Representative Western blot analyses of total 
protein lysates after 2D-gel electrophoresis. Zyxin was detected by using the B72 antibody.  
 
 
 
 
 
Figure 4.14: Protein phosphatase 1 (PP1)-induced zyxin dephosphorylation. 
Representative Western blot analyses of total protein lysates after 2D-gel electrophoresis. 
Lysates obtained from HUVEC exposed to cyclic stretch for 6 hours were either used directly 
(left panel) or following incubation with PP1 at 30°C for 90 minutes. 
 
 
To further analyze whether stretch-induced zyxin phosphorylation via ANP correlates 
with its nuclear accumulation in HUVEC, nuclear protein fractions were prepared and 
investigated. These data are summarized in Figure 4.15.  
Essential differences were observed in all treated samples, as compared to the 
quiescent controls. Exposure to cyclic stretch and ANP again resulted in the detection 
of both an acidic and a neutral isoform in the nuclear fraction, which was essentially 
abolished in the presence of Rp8pGPT-cGMPS (Figure 4.15). 
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Figure 4.15: 2D-gel electrophoresis. Exposure to cyclic stretch and ANP result in the 
nuclear accumulation of zyxin. Western blot analysis of nuclear extracts prepared from 
HUVEC cultured under static conditions (left panels) or exposed to cyclic stretch or ANP      
(1 nM) for 6 hours with or without Rp8pGPT-cGMPS (100 µM, 6 hours pre-incubation) as 
indicated (right panels). The Western blots are representative of four individual experiments 
with essentially the same results. 
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4.1.8 Optimization of siRNA based silencing of zyxin  
To assess the functional role of zyxin in vascular gene expression, a siRNA-based 
knockdown of zyxin gene expression had to be established. Human primary cultured 
umbilical vein endothelial cells are rather difficult to transfect with efficiency (≥70%) 
high enough for gene silencing approaches. As a first approach, metafectene 
transfection was employed by using antisense oligodeoxynucleotides (ODN) 
generated against zyxin, however with only low effects on zyxin expression (Figure 
4.16). Further, a transfection reagent designed for siRNA, RNAiFect (Qiagen, Hilde, 
Germany) was evaluated. For this purpose the functionally validated zyxin-specific 
Hs_Zyx_1HP siRNA (Qiagen) was used. However, also with this approach no 
optimal results were achieved (Figure 4.16). Finally, a magnetofection approach using 
the MATra reagent was explored. The results using this approach are summarized in 
Figure 4.17. With the before mentioned siRNA a sufficient knockdown of zyxin 
(80±5% of control) was achieved after 72 hours of transfection with pre-stretch. The 
scrambled control siRNA had no effect. Interestingly, a short pre-stretching protocol 
further improved the siRNA knock down of zyxin protein, presumably because of a 
high turn over rate of the protein under conditions of tensil stress (Figure 4.17). 
Consequently, this effect was exploited in all consecutive experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Effect of antisense ODN (left panel) and Hs_Zyx_1HP validated siRNA 
(right panel) on zyxin protein level in HUVEC after transfection with either Metafectene 
or RNAiFect, respectively. Exemplary Western blot analyses with relative changes in 
intensity (%) as compared to β-actin band as a loading control. 
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Figure 4.17: Reduction in zyxin protein level after magnetofection. (A) Endothelial cells 
(HUVEC) were transfected using the MaTra transfection reagent with siRNA directed against 
zyxin. Seventytwo hours post transfection the protein was extracted and analyzed by Western 
blot. Zyxin levels in the transfected cells were reduced by 75-85% as compared to the 
untransfected controls when magnetofection and a short pre-stretch protocol was used.             
(B) A 30-minute stretch protocol shortly after magnetofection (right panel) increases the 
efficiency of the siRNA approach. (C) Exemplary immunofluorescence analysis of transfected 
cells using the B71 antiserum. The results are presented as percentage of the basal zyxin 
expression. *P<0.05 vs. control, ***P<0.001 vs. control and scr siRNA control; n=6. 
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4.1.9 Gene expression profiles in endothelial and smooth muscle cells 
subjected to cyclic stretch 
This part of the thesis concentrates to my knowledge on the first systematic analysis 
of stretch-induced changes in gene expression in vascular endothelial cells (HUVEC). 
Using the same approach, the role of zyxin in mechanosensitive gene expression was 
analysed in two models: HUVEC with or without si-RNA-mediated knock down of 
zyxin and cultured aortic smooth muscle cells derived from wild type (C57BL6) and 
strain- and age-matched zyxin-deficient mice. By comparing the mRNA expression 
profiles of endothelial cells subjected to cyclic stretch with cells cultured under static 
conditions (static control) in three independent experiments we aimed at a statistically 
meaningful conclusion. Moreover, knowing of the initial transcriptome changes in the 
transcriptome of both vascular cell types in response to tensile stress should provide a 
first insight into the phenotypic changes occurring in these vascular cells at the onset 
of pressure-induced vascular remodelling (see Chapter 1.1, Figure 1.2). The stretch 
protocol was programmed exactly as described (see Chapter 3.1.4), i.e. 0.5 Hz, 
elongation by 10%, for 6 hours.  
 
4.1.9.1 Quality control of microarray chip data 
For quality control of the microarray data a correlation analysis of the chip intensity 
signals in each subgroup was performed (Park 2005; Lee 2007). The correlation of the 
intensity signals between microarrays in subgroups was calculated and visualized 
using scatter plots for each microarray chip group, respectively. The ideal outcome of 
this analysis would be a strength line (r=1.000), whereas zero correlation (r=0.000) 
would result in a fully random distribution (Tao 2003). Exemplary plot graphs are 
shown in Figure 4.18 for endothelial cells arrays and Figure 4.19 for smooth muscle 
cells arrays. The average correlation between samples for the human endothelial cells 
array was 0.98 (from the highest of 0.9891 in the stretch siRNA group to the lowest of 
0.9704 in the static control), and for the mouse smooth muscle cells was 0.977 (from 
the highest of 0.9927 in the static zyxin-null group to the lowest of 0.9621 in the 
stretch wild type group). 
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Thus, with correlation coefficients close to 1 both experiments can be considered to 
be highly reproducible and thus reliable. All plots showed only trace systemic 
deviations from the line of identity, also indicating a strong correlation between chip 
data in one in the group and good biological and technical conformity of the chip data 
as a whole. 
 
 
 
 
 
Figure 4.18 Exemplary correlation scatter plots of microarray intensity signals for endothelial 
cell RNA samples (subgroups 1, 2 and 3 respectively). Each blot compares the expression 
pattern of one sample with that of another. 
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Figure 4.19 Exemplary correlation scatter plots of microarray intensity signals for mouse 
smooth muscle cell RNA samples (subgroups 1, 2 and 3, respectively). Each blot compares the 
expression pattern of one sample with that of another. 
 
 
 
4.1.9.2 Gene and pathways analysis 
As described in detail before (Chapter 3.2.10), besides listing gene products 
significantly regulated by cyclic stretch in HUVEC or mouse SMC, pathway analysis 
using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway data base, 
GO annotations, and the module map for cancer compiled were performed. The 
microarray Gene Set Enrichment Analysis (GSEA, http://www.broad.mit.edu/gsea/) 
showed significant expression changes in 685 genes by at least 1.5 or 0.67 fold, 
respectively (Figure 4.20) of 129 pathways (Appendix 1) in endothelial cells, and 
significant expression changes in 622 genes (Figure 4.22) of 150 pathways (Appendix 
2) in the smooth muscle cells. The complex KEGG, GO annotations, and the module 
map for cancer compiled analyses revealed a number of cellular pathways which have 
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been associated with stretch-induced vascular remodelling processes before (Table 4.1 
for HUVEC and 4.2 for SMC) but also new pathways which shed some new light on 
the role of zyxin in this process. Zyxin in fact seems to be involved in the differential 
regulation of numerous pathways and gene products (Tables 4.1 and 4.2, marked with 
“+”) 
 
 
Table 4.1: Pathways, as defined by KEGG/GSEA with statistically significant 
differences in the gene expression pattern between groups in the cultured HUVEC. A P-
value of 0.05 was regarded to be significant for pathway analyses; n=3. 
 
 Pathway  EC 
P value  
stretch vs. static  
non affected 
P value  
stretch vs. static 
siRNA zyxin 
Zyxin-
regulated 
pathways 
1. Actin pathway (motility) 0.04849 0.24011 + 
2. CD40 pathway 0.46140 0.00382 + 
3. Cell adhesion molecule activity 0.00596 0.12110 + 
4. Cell proliferation 0.02042 0.00038  
5. Cell signalling 0.00127 0.09292 + 
6. Death pathway 0.19114 0.02236 + 
7. Gα1 pathway  
(cell differentiation) 
0.00625 0.00021  
8. Gα13 signaling pathway  
(proliferation) 
0.16708 0.00127 + 
9. INFγ pathway 0.04859 0.03636  
10. LDL pathway  
(cholesterol transport) 
0.04859 0.31314 + 
11. MAPK pathway 0.01679 0.02225  
12. NFAT pathway  
(apoptosis, T-cell development) 
0.53356 0.00260 + 
13. NFκB induced 0.00048 0.00486  
14. p38 MAPK pathway 0.00424 0.03516  
15. PGC  
(energy metabolism and homeostasis) 
0.00616 0.10373 + 
16. Proteasome pathway 0.00055 0.00002  
17. Ras pathway (apoptosis) 0.52783 0.03140 + 
18. Tgf-β pathway (cell growth, 
differentiation, apoptosis) 
0.00134 0.03474  
19. TNF and Fas network 0.02487 0.02076  
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Figure 4.20: Stretch- sensitive gene products in HUVEC. Volcano plots depicting gene 
products significantly changed in response to cyclic stretch in HUVEC expressing zyxin (A) 
and after RNAi-mediated zyxin knock-down (B). A P-value of 0.001 (dashed line) was 
regarded to be significant for single gene products.  
 
 
 
To evaluate the HUVEC array results, 7 gene products selected for their general 
interest in vascular biology, i.e. interleukin 8, CXCL1, CXC3L1, VCAM-1, ICAM-1, 
MCP-1 and ETB-R were chosen to be analyzed by real time PCR where all gene 
products proved to be mechanosensitive (Figure 4.21). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4.21: Real time PCR analysis of stretch-dependent gene expression in endothelial 
cells. Cells were exposed to 10% cyclic stretch for 6 hours at 0.5 Hz. Real-time PCR analysis 
confirmed differential expression of the selected gene products from the microarray analysis. 
*P< 0.05; **P<0.01 vs. static control; n=4-7. 
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Figure 4.22: Wall tension sensitive gene products in mouse aortic SMC. Volcano plots 
depicting gene products significantly changed in response to cyclic stretch in SMC expressing 
zyxin (A) and in zyxin deficient cells (B). A P-value of 0.001 (dashed line) was regarded to 
be significant for single gene products.  
 
 
 
 
Table 4.2: Pathways, as defined by KEGG/GSEA, with statistically significant difference in 
the gene expression pattern between groups in the cultured mouse SMC. A P-value of 0.05 
was regarded to be significant for pathway analyses; n=3. 
 
 Pathway  maoSMC 
P value  
stretch vs. static  
WT 
P value  
stretch vs. static 
zyxin-/- 
Zyxin-
regulated 
pathways 
1. Cell adhesion 0.39092 0.00483 + 
2. Cell cycle regulator 0.02692                 0.62950          + 
3. Cell motility 0.28311                 0.05545 + 
4. Cell signalling 0.03309                 0.00341  
5. Transcription factors                                                          0.00095         0.26161 + 
6. Death pathway 0.81023                 0.00622          + 
7. EphA4 pathway                                                          0.04405                 0.49705          + 
8. ROS (oxidative stress)                                                        0.03499          0.01598  
9. MAPK pathway 0.04874          0.08453  
10. NFAT pathway 
(apoptosis, T-cell development) 
0.02951 0.03103  
11. p38 MAPK pathway 0.01623 0.51218 + 
12. PGC (energy metabolism  
and homeostasis) 
0.00772 0.28276 + 
13. Proliferation genes                                                              0.01374 0.17233 + 
14. G1 AND S-PHASES (proliferation)                                  0.02113 0.08847 + 
15. Jak STAT pathway  (proliferation, 
differentiation and apoptosis)                                                        
0.38647 0.04646 + 
16. Phosphoinositide-3-kinase pathway                                  0.02428 0.27748 + 
17. VEGF pathway                                               0.06664 0.03189  
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To initially determine whether zyxin differentially modulates stretch-induced gene 
expression in the cultured HUVEC, stretch-induced expression of arbitrarily chosen 
gene products was analysed following zyxin knock-down by real-time RT-PCR and 
compared to cells with normal zyxin expression. On the basic of the microarray 
analysis IL-8, CXCL1, CXC3L1 and MCP-1, the matrix protein versican, the B-type 
endothelin receptor and the cell adhesion molecules VCAM-1 and ICAM-1 were 
chosen. 
As expected, real-time PCR analysis confirmed the microarray data for all chosen 
gene products with respect to their stretch sensitivity (Figure 4.21). Moreover, 
magnetofection of the siRNA directed against zyxin led to a complete inhibition of 
stretch-induced expression of IL-8 (Figure 4.23) as well as CXC3L1 (Figure 4.24, 
panel A) stretch-induced CXCL1 mRNA expression was also clearly reduced 
following zyxin knock-down, however this effect did not gain ststistical significance 
(Figure 4.24, panel B). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Analysis of the role of zyxin in stretch-induced IL-8 expression in 
endothelial cells. Cells were exposed to cyclic stretch for 6 hours as described (3.1.4).             
Real-time PCR analysis revealed that zyxin modulates stretch induced IL-8 expression in 
stretched HUVEC in a zyxin-dependent way. **P<0.01 vs. static control; #P<0.01 vs. stretch 
control; n=4. 
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Interestingly, zyxin knock down did not result in a general alteration of gene 
expression in response to high levels of stretch. Other tested gene products such as 
versican, ICAM-1, VCAM-1, ETB-R and MCP-1 were still stretch inducible also after 
zyxin knock-down (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: Analysis of zyxin-dependent mechanosensitive gene expression in HUVEC. 
Stretch-dependent expression of (A) CXC3L1 mRNA and (B) CXCL1 mRNA in cells with 
and without siRNA.based zyxin depletion. *P<0.05 vs. static control; #P<0.05 vs. stretch 
cells; n=7. 
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4.1.10 Effects of cyclic stretch on IL-8 secretion in HUVEC 
To confirm rthat stretch-induced IL-8 mRNA expression is also accompanied by an 
increased release of this pro-inflammatory chemokine from the endothelial cells, an 
IL-8 ELISA was used. The results shown in Figure 4.25 demonstrate that together 
with the transcription of the IL-8 gene, IL-8 concentrations in the supernatant 
significantly rise in a stretch dependent manner. To confirm that IL-8 secretion also 
accurs in response to ANP as a surrogate stimulus for cyclic stretch the conditioned 
medium was also analysed following ANP exposure. As shown in Figure 4.25, ANP 
also elicted a significant rise in IL-8 protein in the supernatant of the cultured 
HUVEC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: Quantification of IL-8 levels in the supernatant of cultured HUVEC. Huvec 
either kept under static conditions with or without exposure to ANP for 6 hours or exposed to 
cyclic stretch (10% elongation, 0.5 Hz) for the same period. The IL-8 concentration according the 
ELISA is expressed as pg protein per ml supernatant. *P<0.05; ** P<0.01 vs. static control; n=7-9. 
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4.1.11 Analysis of stretch-induced IL-8 expression in HUVEC 
As a result of the microarray analyses ~20% of the stretch-sensitive genes in the 
endothelial cells and ~36% of the stretch-sensitive gene in the smooth muscle cells 
were found to be modulated by zyxin. To corrobarate the crucial role of ET-1 and 
ANP release on zyxin-mediated gene expression, HUVEC were incubated with ANP 
(1 nM) under static conditions with or without the PKG kinase antagonist Rp8pGPT-
cGMPS (100 µM) for 6 hours followed by real-time PCR analysis. 
As shown in Figure 4.26 ANP to some extent mimics the effect of cyclic stretch on 
IL-8 mRNA expression in these cells. Its stimulatory effect was mediated through the 
PKG kinase pathway as evidenced by the inhibitory action of Rp8pGPT-cGMPS 
(Figure 4.26). 
Moreover in the stretched cells exposure to Rp8pGPT-cGMPS resulted in a reduced 
expression of IL-8 mRNA after 6 hours (Figure 4.27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: Effect of ANP on IL-8 mRNA expression in the cultured HUVEC. HUVEC 
were incubated under static conditions with 1 nM ANP alone or in combination with 
Rp8pGPT-cGMPS (100 µM) for 6 hours. Results are expressed as percentage of                             
IL-8/GAPDH ratio in control cells set to 100%. *P<0.05 vs. control; #P<0.05 vs. ANP-treated 
samples; n=10. 
 
 -          +         +     ANP (1 nM) 
 -          -         +     Rp8pGPT-cGMPS (100 µM) 
µM) 
IL
-
 
8 
m
R
N
A
 
(%
 
s
ta
tic
 
co
n
tr
o
l) 
0 
  50 
100
0 
150 
* 
# 
RESULTS   
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Role of PKG in stretch-induced IL-8 mRNA expression. Cells were exposed 
to cyclic stretch for 6 hours in the cultured HUVEC in the absence or presence of Rp8pGPT-
cGMPS (100 µM).  Results are expressed as percentage of IL-8/GAPDH ratio in control cells 
set to 100%. *P<0.02 vs. static control; n= 4-6. 
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4.2 Role of zyxin in vascular structure and function 
The only way to study the role of zyxin in vascular function was the comparison of 
wild type vessels with those derived from zyxin-deficient mice. To this end we 
employed the mice first described by Hoffman et al. (Hoffman 2003) and compared 
them with matched wild type C57/BL-6 mice. 
4.2.1 Phenotype of zyxin-/- mice 
As already reported in the orginal paper by Hoffman et al. zyxin-deficient mice do not 
have an apparent phenotype different form C57BL/6 mice. Comparison of age-
mached zyxin-/- and wild type C57BL/6 mice revealed a similar average body weight 
(approximately 28-32 g) with a slight but not significant tendency of zyxin-deficient 
mice being smaller (not shown). 
Total heart, liver, kidney weight to body weight ratios, were not different between 
knock out and wild type animals. Also histochemistry of all essential body tissues did 
not reveal any distinctive features. Interestingly however, age-mached zyxin -/- mice 
(9 -18 months) had a significantly decreased lung volume as compared to wild type 
C57BL/6 mice (Figure 4.28).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28: Decreased (B) lung weight and (A) size in adult zyxin-/- mice. Data presented 
in panel A are representative for each of the 12 age-matched (9-18 months) animals.         
*P= 0.001; n = 12. 
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4.2.2 Small vessel perfusion 
The set up of a myograph perfusion assay for the measurement of vascular reactivity 
in response to vasoactive substances (Chapter 3.7) addressed the question whether 
zyxin has a role in vascular function or not. As a model the femoral artery was chosen 
because of its diameter and the assistance of relatively few collateral vessels. To 
verify the anatomical and the functional integrity of the isolated blood vessels, 
especially that of the endothelial cell layer, after preparation and pressure perfusion, 
exemplary immuno-fluorescence analyses for the endothelial cell marker proteins 
NOS-3 and CD31 were performed (Figure 4.29). Moreover at the end of each 
experiment the constrictor response to phenylephrine followed by a dilator response 
to acetylcholine was tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29: Exemplary immunofluorescence verification of the integrity of the 
endothelium after equilibration followed by pressure perfusion (60 mmHg) of a femoral 
artery mounted into the pressure myograph. Femoral arteries were either fixed directly 
post dissection or mounted and exposed to high perfusion pressure for 6 to 12 hours. Stability 
of the endothelium during the procedure was monitored by the detection of the endothelial 
markers CD31 (PECAM-1; panel B) and NOS-3 (panel A). As shown on both panels,                  
the endothelium stayed largely intact. 
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4.2.3 Mechanical overload reveals that zyxin is needed for the 
structural stability of the vascular wall 
To study possible consequences of zyxin deficiency on the structure of the vessel 
wall, a histological analysis of crossections of perfused vessels from 3, 6, 9 and                 
18-month old zyxin-deficient mice and age-matched wild type animals was 
performed. Whereas the orientation of medial SMC in vessels from wild type animals 
was stably circumferential also after pressure perfusion in all age groups, there was             
a marked age-dependent reorientation of SMC in zyxin-null mice (Figure 4.30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: Exemplary cross sections of perfused femoral arteries from zyxin-deficient mice. 
Femoral arteries of 9 and 18 months-old mice were isolated, and perfused for 6 hours at  an 
intraluminal pressure of 60 mmHg. Cross sections of zyxin-/- femoral arteries are presented in 
panel B (9 months) and D (18 months), cross sections of wild type femoral arteries in panel A            
(9 months) and C (18 months). Endothelal and media smooth muscle cells are normally developed 
and do not show any pathological alterations in pressure-perfused wild type vessels (A and C) 
whereas the same segments from zyxin-/- mice (B and D) show a rearrangement of the smooth 
muscle cell layer after pressure perfusion in an age-dependent manner. Some cells are framed for 
better visualization of orientation of the cells in the respective sections. 
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4.2.4 Zyxin-dependent response of femoral arteries to pressure  
As a first step in the analysis of zyxin-dependent vascular function, the response of 
freshly prepared endothelium-intact femoral artery segments to increased pressure 
was examined. To this end, vessel segments from animals aged from 3 to 18 months 
were subjected to stepwise increases in perfusion pressure. Comparing the pressure-
induced distention of vessels from young animals did not reveal any differences 
between wild type and zyxin knock-out mice (Figure 4.31 and 4.32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.31: Exemplary presentation of the response of zyxin–deficient (A) and wild 
type (B) femoral arteries (AF, 6 months) to increase in perfusion pressure. Photos where 
taken after each pressure increase by using a live video imaging system. 
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Figure 4.32: Changes in vessel diameter in response to perfusion pressure in femoral 
arteries isolated from 3 months (A) and 6 months (B) old animals. Femoral artery 
segments were isolated from wild type and zyxin null mice and exposed to intraluminal 
pressures raising from 20-120 mmHg. Results are shown as absolute changes in outer 
diameter (µm); n=4-6. 
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In contrast, a marked decrease in compliance was noted in femoral artery segments 
derived from 9 and 18 months old zyxin-deficient mice with a maximum distention 
already at 80 mmHg (Figure 4.35 A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33: Changes in vessel diameter in response to perfusion pressure in femoral 
arteries isolated from 9 months (A) and 18 months (B) old animals. Femoral artery 
segments were isolated from wild type and zyxin null mice and exposed to intraluminal 
pressures raising from 20-120 mmHg. Results are shown as absolute changes in outer 
diameter (µm).*P<0.05; n=3-6. 
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4.2.5 Differential reactivity of zyxin-/- mouse arteries to vasoactive 
agents 
In another set of experiments, the reactivity of zyxin-deficient arteries to 
vasoconstrictors such as phenylephrine and ET-1, and to the vasodilator acetylcholine 
was compared to that of wild type vessels. Control and zyxin-null arteries were 
equilibrated at a pressure of 20 mmHg for a period of 1 hour before starting the 
experiment. Intraluminal pressure was set to 60 mmHg in order to allow dilator as 
well as constrictor responses at the vessel segments. Phenylephrine (at 10 nM,         
100 nM and 1 µM, respectively), ET-1 (at 10 nM, 100 nM and 1 µM, respectively) 
and acetylcholine (100 nM and 1 µM) were added extra-luminally consecutively. 
The reactivity of zyxin-deficient segments to both vasoconstrictors tended to be 
weaker in an age-dependent manner. However, there were no significant differences 
in the response of the vessels from 3 to 6 months old animals to phenylephrine and 
ET-1 treatment (Figure 4.34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34: Exemplary concentration-dependent response of isolated femoral arteries 
from 3-6 months old zyxin -/- or wild type mice to different stimuli. After extension of the 
vessel segments to approximately 250 µm outer diameter, they were constricted with 
phenylephrine (Phe, decrease in outer diameter) followed by endothelium-dependent 
dilatation with acetylcholine (ACh, increase in outer diameter) and constriction again with 
endothelin-1 (ET-1).  
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Also, in 9 and especially in 18 months old animals the constrictor response of the 
zyxin-deficient femoral artery segment was readily apparent (Figure 4.35 and 4.36).  
The dilator response to acetylcholine, on the other hand, was not significantly affected 
in these segments as compared to those from wild type mice, irrespective of the age. It 
can be concluded, therefore, that the NO-mediated endothelium-dependent relaxant 
response to acetylcholine in both types of segments was fully functional, thus 
confirming the uniform quality of the preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35: Exemplary concentration-dependent response of isolated femoral arteries 
from 9 months old zyxin -/- or wild type mice to different stimuli. After extension of the 
vessel segments to approximately 290 µm outer diameter, they were constricted with 
phenylephrine (Phe, decrease in outer diameter) followed by endothelium-dependent 
dilatation with acetylcholine (ACh, increase in outer diameter) and constriction again with 
endothelin-1 (ET-1).  
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Figure 4.36: Exemplary concentration-dependent response of isolated femoral arteries 
from 18 months old zyxin -/- or wild type mice to different stimuli. After extension of the 
vessel segments to approximately 200 µm (WT) and 225 µm (zyxin-/-) outer diameter, they 
were constricted with phenylephrine (Phe, decrease in outer diameter) followed by 
endothelium-dependent dilatation with acetylcholine (ACh, increase in outer diameter) and 
constriction again with endothelin-1 (ET-1).  
 
4.2.6 Effect of zyxin knock-out on pressure induced gene expression 
in situ 
In order to find an explanation for the zyxin-dependent differences in vascular 
reagibility and to evaluate perfusion pressure-induced changes in gene expression in  
arterial segments from zyxin-/- and wild type mice, real-time PCR analysis was 
performed to monitor the expression level of the receptors for the main vasoactive 
agonists, i.e. acetylcholine, noradrenaline, angiotensin II and ET-1 was performed. To 
this end, age-matched femoral arteries were isolated and perfused for 6 hours with           
a pressure gradient of 120 to 40 mmHg. 
This analysis revealed that expression of the AT-1 receptor for angiotensin II and that 
of the ETA-R (Figure 4.37) was up-regulated in response to an increase in perfusion 
0 
  + 
  + 
  + 
 -8 
  + 
 -7 
 + 
-6 
    20 mmHg 
    60 mm Hg 
    Phe 
    Ach 
    ET-1    -6  
  +    + 
   -6 
  + 
   -8 
pa
ss
si
v
e 
v
e
s
se
l d
ia
m
et
e
r 
( µµ µµm
) 300 
250 
150 
175 
200 
225 
275 
 18 months 
wt 
zyx -/- 
RESULTS   
 
77 
pressure in femoral arteries from wild type mice. Conversely, this pressure hence 
stretch-induced AT-1 receptor and ETA-R expression was blunted in segments from 
zyxin-deficient animals (Figure 4.37), suggesting that zyxin mediates the 
biomechanical induction of these genes. In contrast real-time PCR analysis of 
expression of the AT-2 (angiotensin II), M2 (acetylcholine 2) and the M3 
(acetylcholine 3) receptor did not reveal any stretch sensitivity and were also not 
affected by the loss of zyxin (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37: Analysis of AT-1 and ETA-R mRNA expression in isolated pressure-
perfused femoral artery segments from wild type and zyxin-/- mice. AT-1 (A) and ETA-R 
(B) mRNA expression is up-regulated after exposure to a pressure difference of 80 mmHg for 
6 hours in wild type vessel segments. In contrast, zyxin-/- arterial segments increase neither 
the expression of AT-1 (A) nor that of ETA-R (B) in response to pressure perfusion. In the 
case of ETA-R, the expression level even is diminished upon perfusion as evidenced by PCR. 
*P<0.05 vs. WT static control; # P<0.05 vs. WT stretchse control; § P<0.05 vs. zyxin-/- static 
control; n=6. 
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4.2.7 Role of zyxin in regulation of blood pressure 
In this preliminary studies, the deoxycorticosterone acetate (DOCA)-salt model has 
been used as a well-established, clinically relevant model of systemic hypertension. 
Results are representative only for two experiments, performed on zyxin-/- and wild 
type mice each, however with very similar pressure characteristics. Therefore could 
be concidered as distinctive. 
Before the administration of DOCA-salt pellet, zyxin-/- and wild type mice exhibited 
quite comparable systolic arterial pressure (135±28 mmHg; Figure 4.38, panel A), 
whereas diastolic arterial pressure was markable lower in zyxin-/- animals (84.4±10.2 
mmHg) as compared with wild type (106.5±12.5 mmHg) as shown in Figure 4.38, 
panel B.  
After the initiation of DOCA-salt treatment, hypertension was successfully induced in 
all of wild type animals. As shown in Figure 4.38, the hypertensive response was 
consistent throughout the 25 days treatment period. In contrast, treatment of zyxin-/- 
animals with DOCA salt did not provoke the hypertension. Diuring the 25 day period 
the diastolic pressure did not increase in the DOCA-salt-treated zyxin-/- mice and the 
effect was not significantly different among two experiments (Figure 4.38, panel A 
and B). Thus, under basal, unstressed conditions, and after the imposition of DOCA 
salt, zyxin-/-  mice, and at this age, exhibit a anti-hypertensive inclinations.  
Heart rates determined in wild-type and zyxin-/- mice before and after the 
administration of DOCA-salt pellet revealed quite comparable and not significantly 
different values as shown in table, Figure 4.38. 
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Figure 4.38 Representative real-time blood pressure measurement in the DOCA-salt 
model of hypertension.  (A) Mean systolic arterial blood pressure and (B) mean diastolic 
blod pressure in age matched  zyxin-/- and wild type mice before and three weeks after 
DOCA salt treatment. Quantitative results are summarized in table, panel C. 
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5. Discussion 
5.1 The vascular response to increased wall tension 
It is well established that hypertension and, consecutively, pressure-induced vascular 
remodelling are responsible for multiple clinical manifestations of cardiovascular 
disease. Although later phases of these manifestations, such as cardiac insufficiency 
or coronary artery disease have been described in detail at the molecular level, little is 
known about the early changes in endothelial and smooth muscle cell phenotype at 
the onset of the remodelling process. Therefore, we have analyzed which role zyxin 
(Beckerle 1997), a protein recently characterized to be involved in vascular 
mechanotransduction (Cattaruzza 2004), plays in the initial response to chronically 
increased wall tension. 
Mechanical forces in the vascular system 
As discussed in the introduction (Chapter 1.1, see Figure 1.1), two principally 
antagonistic mechanical stimuli, fluid shear stress exceeded by the flowing blood and 
pressure-induced wall tension, modulate the phenotype of endothelial and smooth 
muscle cells in vivo. A balance of these forces is crucial for vascular structure and 
function. If wall tension rises, the affected cells are preferentially stretched 
longitudinally. This deformation, if sustained for longer periods, causes the 
abovementioned phenotype changes of vascular cells resulting in endothelial 
dysfunction and/or smooth muscle cell hypertrophy and proliferation. This stretch-like 
deformation, e.g. the smooth muscle cells, is proportional to the magnitude of wall 
tension which is dependent on both load changes in blood volume hence transmural 
pressure and the internal diameter or radius of the blood vessel (see Introduction, 
Figure 1.1). Therefore, the terms ‘stretch’ and ‘wall tension’ may in fact be used 
synonymously in the context of mechanical overload in the vascular system. 
However, for the sake of clarity, only the term ‘stretch’ is used throughout this 
discussion to describe the consequences of an increased wall tension in vascular cells. 
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High wall tension leads to vascular remodelling 
By changing in the degree of stretch to which affected cells are exposed to, blood 
pressure variations have a major impact on the phenotype of vascular endothelial and 
smooth muscle cells in conduit or resistant arteries. While a transient increase in 
blood pressure results in a compensatory increase in vascular tone, as exemplified by 
the myogenic response (Meininger 1992), chronic pressure overload triggers a 
profound change in gene expression in these cells that ultimately leads to an adaptive 
remodelling of the vessel wall (Lehoux 1998; Lehoux 2006). This is characterized by 
smooth muscle cell hypertrophy, endothelial dysfunction and matrix protein synthesis, 
resulting in an increase in wall thickness. This structural adaptation, although 
effectively compensating for the burden of a supra-physiological increase in stretch, 
essentially fixes the elevated blood pressure (due to the inevitable increase in vascular 
resistance) and therefore is considered to be a hallmark of manifest hypertension 
(Heagerty 1993; Lehoux 1998; Prewitt 2002). 
5.2 Experimental models 
Cyclic stretch as a model to simulate changes in wall tension in vitro 
Human primary cultured endothelial cells and mouse cultured aortic smooth muscle 
cells derived from wild type and zyxin-null animals stretched in a Flexercell unit 
(Flexcell International Corporation, USA) have been used as an in vitro model 
throughout this study. This model has been successfully used as a surrogate stimulus 
for wall tension in the last years (Shrinsky 1989; Cattaruzza 2004; Kakisis 2004; 
Lacolley 2004).  
As shortly outlined above, an increase in wall tension in vivo leads to a longitudinal 
stretching of the medial smooth muscle cells as well as endothelial cell-to-cell 
contacts. This stretch mainly depends on the transmural pressure difference and the 
associated changes in radius of the blood vessel (see Introduction, page 9). However, 
as it is highly difficult to simulate increases in pressure in cell culture models, the 
selective use of the radial component of wall tension, i.e., the mechanical stretching of 
cells, is a well-established model to circumvent this problem. To prevent rapid 
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adaptation of the cultured cells to this stimulus, they are elongated in a rhythmic 
fashion, which does not necessarily reflect the pulsatility of regular blood flow, i.e. 
heart rate. An optimal protocol for cultured endothelial as well as smooth muscle cells 
was found to be an elongation by 10-15% with a frequency of 0.5 Hz for several 
hours. Under these conditions on the one hand a strong increase in wall tension was 
achieved, on the other hand no adverse effects on the viability of the cells was 
observed as it was the case, e.g., when higher stretch frequencies were chosen.  
Besides this merely technical evaluation of the model, also a scientific question arose 
from using cultured cells: Is this short-term in vitro model relevant for the analysis of 
an long-term in vivo process such as vascular remodelling? 
Although preserving many characteristics necessary for survival of cultured cells, 
rapidly lose their ability to regulate many processes compared to the in vivo situation 
(Aird 2007). This loss of “physiological fine tuning” is a major reason for not using 
cell lines for physiological studies. However, as primary cultures of cells were used 
throughout this project, the cells were as near to the in vivo phenotype as possible. 
Likewise, many studies show that major determinants of a physiological phenotype in 
endothelial cells, e.g., the expression of the endothelial isoform of nitric oxide 
synthase (Johnson 2002; Shi 2004) or sensitivity to vasoactive mediators such as 
bradykinin(Derhaag 1996; Miura 2002), are well preserved in freshly isolated cells 
but are lost already in passages as early as p2. Therefore, using freshly isolated 
endothelial cells and smooth muscle cells in passage 2 to 3 only, the response of these 
cells to stretch can be regarded as being close to the physiological range. This can also 
be inferred from the data obtained as discussed below. The careful selection of 
umbilical cords and maximum uniformity of cell isolation and culture (see 3.1.2, 
3.2.10 and 4.1.9) provided some reassurance with regard to the the reproducibility and 
reliability of the results. This was especially important and evident in case of the 
microarray analyses. 
The other major question regarding the use of cultured cells was that these 
experiments were performed in the range of hours whereas pressure-induced vascular 
remodelling in hypertensive patients is a process taking several years if not decades. 
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However, although taking years and being more complex, for neuro-humoral stimuli 
as well as leukocytes like monocytes/macrophages play a role in vascular remodeling 
(Thürmann 1997; Kimura 1998; Martin 2007) – the development of manifest 
hypertrophy as a result of this process occurs multi-stepwise in rather short intervals. 
Why is that? Wall tension or cellular stretch typically rises with an increase in blood 
pressure, which is the consequence of the adaptation of cardiac output to the increased 
flow resistances in hypertensive patients. Thus, as with hypertension, vascular 
remodelling is an adaptive process that aims at compensating actual small increases in 
cellular stretch. Consequently, as a mutual relationship exists between pressure and 
stretch (see Introduction, Figure 1.2), the whole long-term process must be regarded 
as a vicious cycle that time and again repeats itself. For studing the onset of such a 
compensatory phase of the remodelling process, the in vitro model of exposing 
cultured vascular cells to cyclic stretch seems to be ideally suited.  
Zyxin knock out mice 
The availability of a zyxin-deficient mouse strain (Hoffman 2003) enabled us to 
directly analyse the role of zyxin in vascular function. Besides these functional 
analyses using freshly isolated conduit arteries, also an in vivo model for 
hypertension, the DOCA-salt model based on the high increase of volume due to a 
high salt diet plus the effect of the aldosteron-mimetic DOCA (Mills 2000), was 
established.  Both, the in situ analyses of freshly isolated perfused arteries as well as 
the in vivo model will be of fundamental importance to reveal the actual impact of 
zyxin-induced mechanotransduction for vascular function and stretch-induced 
remodelling. Unfortunately, although reported to possess no obvious phenotype 
(Hoffman 2003), zyxin-deficient mice do not mate properly. Therefore, due to 
insufficient offspring, it was not possible to perform enough experiments for a full 
functional analysis of zyxin in vivo. 
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5.3 Signalling pathways activated by stretch 
Mechanotransduction as a major determinant of pathological signalling in the vascular 
system has been in the focus of cardiovascular research for many years (Ingber 1991; 
Davies 1999; Davies 2001; Ingber 2003; Li 2005; Ingber 2006). However, the vast 
majority of signalling pathways characterized to be involved in mechanically induced 
signalling had been described before in other conditions of cellular stress, in particular 
inflammation. This apparent lack of specific “mechanotransduction” pathways has 
been a matter of debate, especially since the vascular response to mechanical 
overload, i.e., stretch, is highly specific. The best example for this variance is the 
particular gene expression pattern induced by stretch in smooth muscle and 
endothelial cells. Although partially “pro-inflammatory”, this response is much more 
complex when compared to a typical inflammatory response in the vascular system 
(see below). 
Pro-inflammatory pathways activated by stretch 
As already outlined in the introduction (Chapter 1.2, page 4), several well-known 
signalling pathways such as the MAP kinase, Rho-ROCK (Lehoux 1998; Tsuda Y. 
2002; Li 2003; Li 2003; Lehoux 2006), and AKT/PI3 kinase pathway as well as many 
others have been described to be activated and functional in response to stretch in 
smooth muscle and/or endothelial cells. These pathways definitely are involved in 
stretch-induced signalling and in gene expression via the activation of several 
transcription factors such as AP-1, C/EBP (Lauth 2000; Wagner 2000; Cattaruzza 
2001; Cattaruzza 2002), NFκB and CREB (Hishikawa 1997; De Martin 2000; Li 
2003). However, all these factors seem not to be essential in the setting of 
mechanotransduction due to the fact that knockdown or inhibition of these pathways 
never resulted in a true inhibition of stretch-induced signalling, but only in a (mild) 
modulation of the cellular response (Lauth 2000; Cattaruzza 2002, Hishikawa 1997; 
De Martin 2000; see also Figure 5.1). Therefore, a specific component of stretch-
mechanotransduction pathway in vascular cells has not yet been identified. 
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5.4 A specific stretch pathway: zyxin as a signalling protein 
 involved in vascular mechanotransduction 
Besides stretch-inducible cation channels potentially involved in the sensing of 
cellular stretch (Lansman 1987; Morris 1990), no signalling pathways particularly 
specific for stretch in vascular cells have been reported. 
The characterization of zyxin as a protein that is down-regulated under pro-
inflammatory conditions in vascular smooth muscle cells (Cattaruzza 2002) triggered 
its analysis as a putative mechanotransducing protein because of its highly suggestive 
structure (Figure 1.3, page 6). This domain structure possibly facilitating its 
interaction with both, the stretch sensor, i.e. focal adhesions, and nucleic acids, 
prompted us to perform preliminary analyses in smooth muscle cells. These 
experiments in fact revealed an involvement of zyxin in mechanotransduction 
(Cattaruzza 2004) and lead to the formation of a working hypothesis for stretch-
induced signalling in SMC (Figure 5.1). In parallel, another study analysing the 
function of a homologous protein, the Muscle LIM Protein (MLP), in cardiomyocytes 
with similar results (Knöll 2002) further substantiated the hypothesis that zyxin might 
be the long sought specific mechanotransducing protein responsible for the typical 
response of vascular cells to supra-physiological levels of stretch. 
 
 
 
 
 
 
 
 
Figure 5.1: Mechanotransduction in SMC. Common and specific stress pathways are 
activated in response to supra-physiological levels of stretch in vascular smooth muscle cells. 
Only the combination of both, common stretss pathways and the activation of the specific 
mechanotransducer zyxin is thought to result in the unique phenotype changes observed in 
vascular cells during the onset of stretch-induced remodelling of the vessel wall. 
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Zyxin as a component of focal adhesions 
Zyxin is predominantly located in focal adhesions and, in response to stretch, is also 
recruited to stress fibers. Besides the N-terminal domain, mediating its association to 
focal adhesions (Beckerle 1997), zyxin has a C-terminal LIM-domain comprising 3 
zinc-finger motifs known to mediate protein-protein and/or protein-DNA interactions 
(Schmeichel 1994). Originally, zyxin was characterized as a protein coordinating the 
organization of actin filaments at focal adhesions and cell-to-cell contacts in 
fibroblasts and epithelial cells (Crawford 1991; Crawford 1992; Reinhard 1995; 
Hoffman 2006). Thus, zyxin is likely to function as a structural protein in endothelial 
cells, too. Similar to our initial observations, it has been described that zyxin 
undergoes a major redistribution into newly formed stress fibers also in fibroblasts if 
exposed to cyclic stretch (Yoshigi 2005). However, these authors could not confirm a 
nuclear localization of zyxin. Our initial explanation that this might be due to the 
different cell types analyzed has been further substantiated as fibroblasts generally are 
insensitive to atrial natriuretic peptide and thus do not possess high activities of 
protein kinase G, the principal effector kinase of this signalling pathway which is 
crucial for the nuclear translocation of zyxin (see below). 
Zyxin is released from focal adhesions in response to stretch and accumulates in the 
nucleus 
The second function of zyxin, shown in this study, is that of modulating stretch-
induced gene expression in endothelial (as well as in vascular smooth muscle) cells. 
Thus, within minutes zyxin translocates to the nucleus of endothelial cells exposed to 
cyclic stretch and modulates the expression of mechanosensitive genes. 
Zyxin immunofluorence analysis of stretched cultured HUVEC revealed that the 
protein similar to the situation in rat SMC (Cattaruzza 2004) translocates from focal 
adhesions to stress fibers and the nucleus. Surprisingly, time course analyse revealed a 
highly dynamic distribution of zyxin in stretched endothelial cells. Besides the 
aforementioned fast phase of nuclear accumulation, zyxin was redistributed to its 
cytoskeletal contacts, i.e., focal adhesions and stress fibers within 120 minutes after 
the onset of stretch. Extended phases of stretch (>360 minutes), on the other hand, 
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resulted in a stable localization of the protein in the nucleus with marked changes in 
the transcriptome that were reminiscent of the phenotype changes typical for the onset 
of vascular remodelling (Lehoux 1998; Lehoux 2006). Although the mechanism 
underlying the highly complex shuttling of zyxin into and out of the nucleus could be 
elucidated to some extent, the teleological background for this highly regulated event 
remains unclear. So, what may be the reason for this biphasic kinetics of zyxin 
translocation to the nucleus? 
One reason might be that the fulminant initial and fast release of atrial natriuretic 
peptide, a crucial mediator in zyxin translocation in vascular cells (see below), just 
causes a pre-mature translocation, which then is “repaired” by a rapid redistribution of 
zyxin without any functional consequences. Then, in case of prolonged exposure to 
supra-physiological levels of stretch, the consecutive and constant release of ANP 
may induce the final and functional translocation of zyxin. 
However, as such, an ultimately irreversible initiation of a remodelling process is a 
complex and potentially serious interference with vascular function, compensatory 
wall thickening should only take place when the structure of the vessel wall is truly 
insufficient. To this end, the fast nuclear translocation of zyxin may also serve as a 
last attempt to retain vascular function by a more transient approach, e.g., by 
increasing intracellular calcium concentrations and/or energy metabolism. Although 
speculative, the hypothesis that in a first step zyxin-induced gene expression may aim 
at increasing the ability of the affected vessel to respond to vasoactive substances 
such as endothelin-1 and noradrenaline is attractive. An increased expression of the 
receptors for the aforementioned mediators would in fact lead to a rise in intracellular 
Ca2+ and, consequently, a better capacity for constriction. Further, it may be 
speculated that, if this response was sufficient, the remodelling program may be shut 
down at this point with zyxin returning to focal adhesion points. On the other hand, if 
supra-physiological levels of stretch were still prevalent – as it was the case in the 
experiments performed in this study – zyxin would again shuttle to the nucleus to 
ultimately change the gene expression profile, thus irreversibly changing the 
phenotype of the affected vascular cells. A scheme of this two-step hypothesis can be 
found in Figure 5.2. 
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Figure 5.2: Hypothetical two-step model of the vascular response to 
supraphysiological levels of stretch. Upon exposure to an increased level of stretch, 
zyxin is released from focal adhesions and accumulates in the nucleus. Here, initial 
changes in gene expression, along with a rapid redistribution of zyxin, may lead to the 
retaining of vascular function despite the high level of mechanical strain, and eventually 
shut down the remodelling process. In the presence of constantly elevated levels of 
stretch, the second phase of nuclear translocation may be initiated and, as a consequence, 
changes in the gene expression pattern that are typical for vascular remodelling. 
 
A common mechanism for sensing stretch: Atrial natriuretic peptides in the heart and 
in arteries 
In the course of this study the signalling events leading to the release of zyxin from 
focal adhesion contacts and its redistribution to stress fibres and to the nucleus could 
be elucidated. A surprisingly complex chain of events, namely the stretch-induced 
release of endothelin-1 which in turn induces the expression and release of atrial 
natriuretic peptide (ANP), was responsible for the complex redistribution of zyxin 
observed in stretched endothelial cells. ANP, via its receptor(s) NPR-A(B), triggered 
the activation of the protein kinase G and, finally, the phosphorylation of zyxin. This 
phosphorylation was necessary (i) to release zyxin from focal adhesions and (ii) to 
allow the nuclear accumulation of zyxin as shown by PKG inhibition and 2D-
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gel/Western blot analysis of total cellular protein and nuclear protein fractions from 
stretched and ANP-treated endothelial cells. A schematic overview of this signalling 
pathway can be found in Figure 5.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Model of stretch-induced release and nuclear translocation of zyxin. The 
consecutive release of ET-1 and ANP causes activation of the respective receptors (ETB-R 
and NPR-A) and a cGMP-mediated activation of protein kinase G (PKG). PKG then 
phosphorylates zyxin thereby inducing the release from focal adhesions (FA) and its 
translocation to the nucleus. Here, zyxin modulates gene expression in a complex way 
(see below), directly, as a transcription factor, or indirectly, by protein-protein interaction.  
 
Again, addressing the suprisingly complex kinetics of zyxin translocation, discussed 
above, one observation might explain the early translocation of zyxin to the nucleus at 
a mechanistic level. However, the teleological background remains speculative (see 
5.5, page 94). In contrast to endothelin-1, ANP is stored in vesicles similar to von 
Willebrand factor (vWF) (Weibel 1964; Wagner 1982) in endothelial cells. In contrast 
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to endothelin-1, ANP is stored in vesicles similar to the typical storage of von 
Willebrand factor (vWF) (Weibel 1964; Wagner 1982) in endothelial cells. Therefore, 
an initial stretch-induced increase in intracellular calcium may – similar to that 
observed for von Willebrand factor in the case of vascular injury (Kermode 2002) –
cause a virtually explosive release of ANP. This rapid ANP release could in fact be 
detected in cell culture supernatants of endothelial cells within 1 minute after starting 
of the stretch protocol and without any supporting endothelin-1 release (Figures 4.6 
and 4.7). This rapid ANP release may be mediated through the activation of stretch-
sensitive non-specific cation channels (Lansman 1987; Morris 1990). However, 
whether this initial zyxin translocation is more like an accident owed to the initial 
stretch-induced depolarization of endothelial cells without any functional relevance or 
whether it actively contributes to the two-step process described above (Figure 5.2) 
remains to be elucidated. 
Another point that needs to be clarified is the actual nature of the ANP receptor 
involved in the aforementioned signal transduction process. Unfortunately, no reliable 
experimental tools such as NPR-B antibodies, receptor-specific agonists or 
antagonists are currently available. As the cGMP-induced activation of PKG is 
fundamental for downstream signalling, only the membrane-bound guanylate cyclases 
NPR-A and NPR-B can be involved therein (see the Introduction 1.5, page 9). 
Although both natriuretic peptide receptors are expressed in endothelial cells, mRNA 
levels of NPR-B are rather low. Moreover, the cellular distribution of NPR-A, for 
which antibodies are aviable, was clearly altered in response to stretch. As in 
quiescent endothelial cells, most of the receptors seem to be localized in a vesicular 
compartment, while stretch leads to an equal distribution to the cell membrane. 
Therefore, without definitive proof for this assumption, NPR-A most probably is the 
receptor responsible for stretch-induced ANP-mediated signalling in human 
endothelial cells. 
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Local ANP and systemic ANP: variations on one theme  
Why is the endothelial cell signalling in response to cyclic stretch so complicated? It 
is well-known for sometime that the release of ANP from atrial monocytes into the 
blood is regulated in a very similar way (Ruskoaho 1886; Lang 1985; Kinnunen 1993; 
Dietz 2005). As described in the introduction, ANP is released from the atria in 
response to high filling during diastole, i.e. in response to volume hence pressure-
induced stretching of the atrial wall. The cells actually sensing this stretch are the 
atrial endothelial cells, which in turn release endothelin-1. Endothelin-1 – similarly as 
described here for endothelial cells – then induces the release of ANP through 
activation of the ETA-R from the atrial myocytes. ANP circulating in the blood acts 
both on blood vessels to decrease pheripherial resistance and the kidnes to enhance 
sodium and water secretion and thus lower blood volume and pressure. In the context 
of systemic volume control, this complex multi-cell pathway makes perfect sense: 
whereas one cell type (endothelial cells) senses and transduces the actual stimulus for 
the release of ANP, the next (atrial myocytes) is responsible for propagation of the 
signal through ANP synthesis and discharge. Finally, effector cells in the vasculature 
and the kidney receive the signal and execute the program, i.e. they effectively reduce 
the circulating blood volume thereby closing the control circuit through elimination of 
the activating stimulus, i.e. atrial wall stretch. Interestingly, together with the release 
of ANP zyxin may be localized in the nucleus of cardiomyocytes (Smolenski 2000; 
Kato 2005). Thus, all building blocks of the vascular stretch sensor characterized for 
the first time in this study seem to be preformed, “available” and active in multiple 
cells throughout the organism and must be reassembled in just one cell type, the 
endothelial cell (and to some extent the vascular smooth muscle cell), for designing an 
autocrine stretch sensor and effector system. Therefore, the initial amazement 
regarding the highly complicated endothelial signalling pathway for “just” releasing 
zyxin from focal adhesions, may be replaced by an admiring the effective use of pre-
existing signaling building blocks for a different task. 
Thus, the effector pathways for relieving systemic and local vascular wall tension 
seem to be quite different while the actual stimulus, stretching of cells is the same. 
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This way, highly efficient and sensitive sensor and signalling pathways can be 
preserved. 
Zyxin in the nucleus: stretch-induced gene expression in vascular cells 
The basis for the phenotype changes of vascular cells observed in pressure-induced 
vascular remodelling is a complex alteration of gene expression that specifically 
promotes this process. Up to now only a very limited number of preliminary reports 
describing the effects of stretch on vascular smooth muscle or endothelial cells at this 
molecular level have been published (Resnick 1995; Obuwole 1997). In particular, no 
complex and statistically valid screening of the endothelial or smooth muscle cell 
transcriptome in response to stretch has been described. 
In this study, the first systematic analysis of stretch-induced changes in endothelial as 
well as smooth muscle cell gene expression has been performed based on statistical 
significance. In the literature, a vast number of microarray analyses can be found 
comparing tissues or primary cells. However, although such an approach from a 
physiological point of view is correct, many of these studies suffer from the 
considerable variability of the samples used for analysis (Park 2005; Lee 2007). To 
really achieve statistical significance with only three independent microarray 
analyses, we aimed at using cells as comparable as possible by taking care of 
absolutely uniform conditions from isolating the cells to harvesting the RNA samples 
for all experiments (for details see 3.2.10). The optimal uniformity, thus quality, of 
our microarray experiments was retro-spectively checked by analyzing several known 
stretch-inducible gene products. As verified by microarray signal intensity analysis 
(Tao 2003; see also page 57), the series of experiments analyzed was in fact highly 
comparable and reproducible. To evaluate and confirm the microarray data, real-time 
PCR analysis of several randomly chosen gene products was performed. All gene 
products re-tested were stretch-sensitive, thus corroborating the reliability of the 
microarray analyses. 
The pathway analysis (Manoli 2006) performed with the computational tool gene set 
enrichment analysis (GSEA) not only allowed to determine the transcriptional profile 
(Mootha 2003; Subramanian 2005), but also facilitated the understanding of the 
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complex changes in gene expression by grouping differentially expressed gene 
products into functional pathways. It thus provided a physiologically highly 
significant and meaningful interpretation aid for the large amount of data generated by 
microarray analyses. Thus, this analysis tool provides far more than just a list of 
single gene products.  
Besides a substantial amount of new data, several pathways, reported to be involved 
in stretch-induced vascular remodelling in one or the other way, could be confirmed 
to be in fact stretch-inducible both in endothelial and smooth muscle cells. Among 
these pathways, cell proliferation (Lee 1995), migration (Dajnowiec 2007), 
differentiation (Haga 2007) and apoptosis (Cho 1995; Hamet 1996; Cattaruzza 2000) 
were most prominent. Moreover, also biochemical pathways such as energy 
consumption (Deedwania 2004), cytoskeletal remodelling and oxidative stress           
(Cai 2000; Touyz 2001; Touyz 2004; Fortuño 2005) were confirmed to be affected. 
Most interesting, however, was the exact characterization of several signalling 
cascades such as the MAP kinase pathways as well as the activation of transcription 
factors such as AP-1, C/EBP or NFAT, which all have been implicated in vascular 
remodelling as well as cardiac hypertrophy (Agrotis 1996; Lauth 2000; Cattaruzza 
2001; Intengan 2001; Luft 2001). 
The second major question addressed by this analysis was, if and in which way zyxin 
is involved in the stretch-induced reprogramming of the endothelial and smooth 
muscle cells transcriptome. The careful and effective knockdown of zyxin using a 
specific siRNA (see page 55) and in parallel the comparison of aortic cultured smooth 
muscle cells derived from wild type and zyxin-deficient mice confirmed the 
fundamental influence of this protein on stretch-induced gene expression. According 
to these analyses, zyxin is involved in the regulation of ~20% (EC) and ~36% (SMC) 
of all stretch-sensitive gene products. Most of these gene products can be arranged in 
pathways which are of special importance for pressure-induced vascular remodelling. 
In particular, zyxin is important for the expression of gene products involved in cell 
migration and proliferation, protection from apoptosis and high energy consumption 
(see Results, page 60 and 63, Tables 4.1 and 4.2). Moreover, uptake as well as 
synthesis of cholesterol depends on zyxin signalling in endothelial cells. 
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Does zyxin-induced gene expression reflect early phases of remodelling and 
endothelial dysfunction? 
All zyxin-dependent pathways defined above tend to promote vascular remodelling in 
endothelial as well as smooth muscle cells. These processes are specific for 
endothelial dysfunction and hypertrophic and/or hyperplastic growth of the vessel 
wall. Therefore, the hypothesis that zyxin is critically important for stretch-induced 
vascular remodelling is highly suggestive when considering the aforementioned 
microarray data. 
Another aspect of zyxin-mediated gene expression in endothelial cells is the possible 
involvement of the protein in the development of atherosclerosis. Hypertension, hence 
chronic exposure to supra-physiological levels of stretch constitutes an important risk 
factor for the development of this disease. Interestingly, also cholesterol metabolism 
is influenced by zyxin in stretched endothelial cells. As this molecule, especially in 
connection with the high levels of oxidative stress observed under conditions of 
mechanical overload, plays a central role in the early development and maintenance 
of atherosclerosis, zyxin-mediated uptake and synthesis of cholesterol might well play 
a role in the early sub-endothelial accumulation of oxidized cholesterol (Witztum 
1991; Pillarisetti 1997; Skålén 2002; Birukov 2007). Moreover, several chemokines 
such as IL-8, which seem to be essential for the recruitment of leukocytes to the early 
atherosclerotic lesion are expressed under the control of zyxin. IL-8 is a well known 
chemoattractant for neutrophils (Detmers 1990; Rollins 1997; Zlotnik 2000; Patterson 
2002),  T-lymphocytes (Larsen 1989) and monocytes (Mukaida 1998; Gerszten 1999).  
The levels of zyxin-dependent endothelial IL-8 secretion in response to stretch at least 
match those of activated peripheral blood monocyte/macrophages (20±6 ng/mg as 
cellular protein measured by ELISA from Figure 4.25 vs. 25±5 ng/mg cellular protein 
for macrophages; Persson 2006). Thus, the stretch-induced release of IL-8 from 
endothelial cells alone may be sufficient for monocyte recruitment in the early stages 
of atherosclerosis (Mukaida 1998; Gerszten 1999). Together with the imbalance in 
cholesterol metabolism discussed above, stretch-induced and zyxin-mediated 
endothelial gene expression might be an important factor strongly facilitating and 
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promoting the formation of early atherosclerotic plaques (Chobanin 1996; Lehoux 
2006).  
5.5 Zyxin and vascular function  
Zyxin-deficiency and vascular function – a matter of gene expression? 
Besides its signalling properties, zyxin is thought to be important for the organisation 
of the actin-myosin system and its connection to the extracellular matrix via focal 
adhesions and stress fibres. Therefore, a second aim of this study was to characterize 
whether zyxin indeed modulates vascular structure and tone. To this end, an in situ 
perfusion model with defined flow conditions was chosen and adapted for isolated 
mouse femoral arteries. With the access to zyxin-deficient mice, the role of zyxin in 
vascular function could be ideally addressed in this model.  
Interestingly, the first description of zyxin knockout mice available to us neither 
revealed any functional phenotype nor was able to demonstrate any morphological 
changes as a result of zyxin deficiency (Hoffman 2003). However, in this study only 
relatively young mice (>6 months) were analysed. While herein always gender and 
age-matched (from 3 to 18 month old) animals were investigated side by side with a 
major focus on the vasculature. This way we could demonstrate fundamental 
differences in both structure and function of freshly isolated perfused femoral arteries 
derived from wild type and knockout mice. By inspection, the vessels from wild type 
mice appeared to be mechanically more stable than those from zyxin knockout 
animals. Consequently, preparation of the femoral artery from wild type mice was 
easy and the mounting unproblematic, whereas vessels obtained from zyxin-deficient 
mice were brittle and easily disrupted pointing to a major difference in structure and 
matrix composition.  
While distension in response to different levels of pressure was similar in all arteries, 
the comparative analysis of the response to vasoconstrictor substances such as 
phenylephrine and endothelin-1 revealed an impaired ability of zyxin-deficient 
vessels to constrict. Most surprisingly, in vessels from older animals a complete 
rearrangement of smooth muscle cells in response to pressure perfusion could be 
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observed. The new perpendicular orientation of the cells, on the one hand, helped to 
explain the weak constrictor response since even a good contractility of cells oriented 
longitudinally could not result in efficient (concentric) constriction (see Figure 4.30, 
page 70). On the other hand, the reason for this complete rearrangement of the 
somooth muscle cells in the media remains to be determined and thus far is 
unparalleled in the literature. One starting point for approaching this amazing finding 
would be a thorough analysis of the composition of the extracellular matrix. Due to 
insufficient numbers of mice, however this analysis could not be done yet.  
The few in vivo experiments possible revealed another fascinating aspect of vascular 
function in zyxin-deficient mice. These mice responded with a surprisingly low 
increase to DOCA-salt treatment when compared to wild type animals. Moreover, 
monitoring of blood pressure revealed a rather low diastolic pressure and a large 
pressure pulse in zyxin-deficient animals. These data point to a low resistance and a 
low (i.e. bad) compliance of the arterial system in these animals. At first sight, 
especially in view of the perfusion data, this seems to be contradictory, even 
paradoxical, since physiologically a high compliance together with a relatively low 
resistance are regarded as “healthy” and, vice versa, in most pathological conditions 
low compliance is accompanied by high resistance. However, at second sight, these 
findings may become interpretable. 
Zyxin-deficient arteries: weak resistance and low compliance - paradox behavior due 
to altered gene expression? 
Zyxin is an important regulator of vascular gene expression. Besides the expression of 
receptors for vasoconstrictors as analyzed in the vessel segments after pressure 
perfusion (see Results, page 76 and 77), the protein also strongly modulates the 
expression of matrix proteins. Reanalysis of the smooth muscle cell microarray data 
on the single gene level revealed a striking imbalance in the expression of several 
collagen isoforms and the matrix proteins fibronectin and tenascin-C. Whereas wild 
type cells respond to stretch with the expression of the stabilizing matrix protein 
fibronectin (Ohashi 1999) and collagen isoforms responsible for stabilization and 
maintenance of the cellular phenotype (Leung 1976; Li 1998), zyxin-deficient cells 
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predominantly express the proliferation-associated matrix protein tenascin-C (Mackie 
1997; Feng 1999; Jones 2000; Cattaruzza 2004) as well as collagen isoforms 
characteristic for other tissues.   
Overall, zyxin deficiency implies a completely altered matrix composition. How may 
this explain the finding that both compliance resistance are lower than expected? A 
short consideration of the situation in the venous system may be helpful. Generally, 
the compliance of veins is considered very high, as they can “store” rather large 
volumes without a major increase in pressure.  This is mostly due to the phenomenon 
that these vessels are rarely fully extended by the blood filling them. In fact, if a vein 
under high-pressure conditions is completely filled with blood, its compliance tends to 
be even lower than that of comparable arteries (see any physiology textbook). 
Keeping in mind the low mechanical stability of zyxin-deficient vessels, the impaired 
receptor expression and matrix production and their easily disturbed smooth muscle 
cell-matrix interactions, as demonstrated by the rearrangement of smooth muscle cells 
in response to pressure perfusion, a vein-like behavior of these arteries does not seem 
too far-fetched. 
In the arterial system, blood filling is always high (due to the high pressure) and in 
this case, the compliance might be low. On the other hand, if the caliber of the vessel 
is normal but its capacity to constrict is weak, the resistance may be also low. This 
seemingly paradox mixture of vascular (dys-)function due to zyxin-deficiency may be 
explained by an imbalanced gene expression in affected animals.  
In light of the above, it is quite surprising that the vascular phenotype of zyxin-
deficient mice is relatively mild and only becomes apparent in the second year of their 
life. Two principal reasons may account for this. First, wild type mice naturally never 
develope hypertension. Thus, without a challenge resulting in high levels of 
mechanical strain, vascular dysfunction due to a loss of zyxin-induced gene 
expression may never become apparent. Secondally, these animals are much less 
active than their age-matched counterparts. They show less interest in social contacts, 
playing and mating, thereby potentially avoiding any cardiovascular stress that could 
jeorpadize their cardiovascular function. This may be part of a compensatory 
mechanism that zyxin-deficient mice employ in order to survive despite an impaired 
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vascular function. Such compensatory phenomena are well characterized in other 
knockout mice. In cardiovascular physiology, the most prominent example is that of 
endothelial nitric oxide synthase-deficient mice. These animals were expected to 
suffer from severe hypertension. However, as other vasodilator molecules partially 
substitute for the loss of nitric oxide, the phenotype is relatively mild (Huang 1995; 
Shesely 1996; Liu 2008). 
5.6 Perspective 
The present study provides an almoust conclusive description of the mechanisms 
underlying the stretch-induced release of zyxin from focal adhesions and its 
accumulation in the nucleus. Moreover, the systematic analysis of zyxin-dependent 
endothelial and smooth muscle cell gene expression provided multiple insights into 
stretch-induced vascular remodelling and the potential role of zyxin therein. Finally, a 
first exploration of the role of zyxin in vascular function under physiological 
conditions was presented. 
Based on these findings, several interesting and fundamental questions arise that will 
be addressed in the future: 
1) What is the actual mechanism of zyxin-induced gene expression? Is zyxin a 
transcription factor or does the protein act at a more global level? In this 
context, we could characterize a stretch-responsive promoter element, the 
pyrimidine-purine box, in the most zyxin-dependent genes. It is not clear yet, 
however, whether zyxin binds directly or indirectly to this motif. 
2) In light of the new and detailed information regarding stretch-induced gene 
expression, early changes in endothelial and smooth muscle cell phenotype 
should be approached on a functional level. Such analyses could encompass 
the role and mechanism of apoptosis, proliferation and different signalling 
pathways in vitro and in vivo. In this regard, the generation of a cell-specific 
conditional zyxin-knockout mouse, which is currently under way, will be of 
great help.  
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3) With a better supply of zyxin-deficient mice, two central questions may be 
addressed in more detail. First, does the lack of zyxin-induced gene expression 
account for the weak vascular structure and function in zyxin-deficient mice? 
To this end, zyxin-dependent gene and protein expression will be analyzed in 
situ and in vivo. A special focus will be on the expression of matrix proteins. 
Secondly and maybe most interesting: Is zyxin a promising target to interfere 
with stretch-induced vascular remodelling? By employing a hypertension 
model with wild type and zyxin-deficient mice it should be possible to analyze 
whether zyxin is in fact a critical determinant of stretch-induced vascular 
remodelling. Further, if zyxin is indeed responsible for this process, one could 
design strategies to interfere with it in vivo, e.g. by the use of decoy 
oligonucleotides (Morishita 1996; Tomita 1997; Wagner 2000) possessing the 
sequence of the pyrimidine-purine box and, therefore able to selectively inhibit 
the zyxin-dependent gene expression. 
 
These projects will lead not only to a better understanding of the principles of 
mechanotransduction in vascular cells, but may also help to define a new therapeutic 
approach to prevent an exaggerated stretch or pressure-induced remodelling process, 
as e.g. in arterial hypertension. 
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6. Summary 
Hypertrophy in conduit and hyperplasia in resistance-sized arteries is the clinically 
visible outcome of a supra-physiological pressure-induced stretching of endothelial 
and smooth muscle cells, e.g. in arterial hypertension. This adaptive remodelling of 
the vessel wall in response to mechanical overload results in the fixation of vascular 
resistance at devoted levels and, therefore, is a major contributor to coronary heart 
disease, dilated cardiomyopathy and stroke. Although phenomenologically 
characterized in detail, the signal transduction pathways underlying the stretch-
induced shift in vascular gene expression and, consecutively, long-term phenotype 
changes of endothelial as well as smooth muscle cells are still poorly understood.  
In this thesis, the first specifically mechanotransducing protein in endothelial cells 
could be defined with the focal adhesion protein zyxin. Moreover, it could be shown 
that zyxin after nuclear translocation orchestrates stretch-induced gene expression in a 
highly complex way. By comparing isolated perfused arteries from wild type and 
zyxin-deficient mice, it could be further demonstrated that zyxin plays a decesive role 
in maintaining vascular structure and function under conditions of high perfusion 
pressure. 
Supra-physiological levels of stretch caused a dissociation of zyxin from focal 
adhesions in endothelial cells. This event was mediated by the consecutive stretch-
induced release and coordinated action of endothelin-1 (ET-1) and atrial natriuretic 
peptide (ANP). The ET-1-mediated release of ANP resulted in a presumably A-type 
natriuretic peptide receptor-mediated, cGMP-induced activation of protein kinase G, 
which in turn phosphorylated zyxin, thereby facilitating its dissociation from the focal 
adhesions and accumulation in the nucleus. This complex stretch-induced signalling 
cascade described herein for the first time for endothelial cells, closely resembles the 
multi-cellular events preceding the cardiac release of ANP. Thus, endothelial cells are 
not only able to sense stretch, but also specifically transduce and respond to 
mechanical overload by activating the newly characterized mechanotransducer zyxin. 
Moreover, the first systematic genome-wide microarray analysis of human endothelial 
and mouse vascular smooth muscle cells revealed a highly complex – albeit similar – 
response of these cells to mechanical overload. Against the background of the long 
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known effects of chronic stretch in the arterial system, namely hypertension, the 
microarray results obtained are highly suggestive. In both cell types, more than 600 
gene products were differentially expressed in response to cyclic stretch. These could 
be grouped into in several well-defined cellular pathways that are known to be crucial 
for the development of hypertrophy and/or hyperplasia in the course of vascular 
remodelling. Most interesting, a parallel microarray analysis comparing zyxin-
deficient stretched endothelial and smooth muscle cells with their zyxin-expressing 
counterparts revealed that zyxin is fundamental for the changes in gene expression 
preceding stretch-induced vascular remodelling processes. Zyxin suppression would 
thus result in the inhibition of pro-hypertrophic pathways, e.g. by a shift towards pro-
apoptotic gene expression, but also may affect signalling pathways involved in normal 
vascular function. 
Finally, by using freshly isolated perfused segments of the mouse femoral artery from 
wild type and zyxin-deficient mice, it could be demonstrated that vascular function 
depends on the presence of zyxin. Although the phenotype of zyxin-deficient mice is 
mild in young animals, vascular function and structure is strongly impaired in aged 
mice. Vasoconstriction and, thus, the ability for the regulation of flow resistance, is 
strongly diminished in zyxin-deficient animals. This effect most probably occurs due 
to missing zyxin-induced expression. The crucial function of zyxin in vascular 
physiology could be further substantiated by initial experiments employing the 
DOCA-salt hypertension model in wild type and zyxin-deficient mice. 
In conclusion, besides thoroughly analyzing stretch-induced zyxin signalling and gene 
expression in vascular cells, this thesis provides some interesting insights into the 
pathophysiological relevance of this molecule, which in the future may be decisive to 
develop novel therapeutic strategies against hypertension-induced alterations in 
vascular structure and function. 
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Appendix 1:  
 
 Pathway  EC 
P value  
stretch vs. static  
non affected 
P value  
stretch vs. static 
siRNA zyxin 
Zyxin-
dependent 
pathways 
1. Actin y pathway 0,04849 0,24011 + 
2. Agpcr pathway 0,46141 0,04038 + 
3. Akap 96 pathway 0,01029 0,16243 + 
4. Akap 13 pathway 0,46141 0,04038 + 
5. Akt pathway 0,31388 0,00554 + 
6. Androgen up genes 0,00000 0,00007  
7. Arap pathway 0,04368 0,05357 + 
8. Arginine C pathway 0,22713 0,03980 + 
9. B lymphocyte pathway 0,02209 0,03448  
10. Bad pathway 0,05592 0,00343  
11. Breast cancer estrogen signalling 0,00195 0,02972  
12. Ca nf at signalling 0,25428 0,03386 + 
13. Cardiac egf pathway 0,25033 0,02368 + 
14. Carm1 pathway 0,31389 0,02635 + 
15. Ccr5 pathway 0,21545 0,00390 + 
16. CD40 pathway 0,46141 0,00382 + 
17. Cell adhesion molecule activity 0,00596 0,12110 + 
18. Cell cycle 0,00353 0,00405  
19. Cell cycle arrest 0,01876 0,04840  
20. Cell proliferation 0,02042 0,00038  
21. Chrebp pathway 0,35843 0,00834 + 
22. CAM 0,00001 0,00007  
23. Cell cycle 0,00576 0,07400 + 
24. Death 0,03593 0,09764 + 
25. DNA met and mod 0,03859 0,13494 + 
26. Signalling 0,00127 0,09292 + 
27. Creb pathway 0,32589 0,01489 + 
28. Death pathway 0,19114 0,02236 + 
29. Downregulated by hoxa9 0,00159 0,09764 + 
30. Drug resistance and metabolism 0,13717 0,02506 + 
31. Electron transport chain 0,92179 0,03116  
32. Electron transporter activity 0,02333 0,26126  
33. EMT down 0,03095 0,02220  
34. EMT up 0,00009 0,00012  
35. Erbb3 pathway 0,02735 0,02220  
36. Erythrocyte pathway 0,01208 0,07748 + 
37. Fcer1 pathway 0,20173 0,02829 + 
38. Fetal liver hs enriched TF jp 0,00006 0,00139  
39. Fmlp pathway 0,48516 0,01868 + 
40. Frasor er down 0,00094 0,00123  
41. G1 pathway 0,00625 0,00021  
42. G13 signaling pathway 0,16708 0,00127 + 
43. G2 pathway 0,02303 0,01697  
44. Gata3 pathway 0,35843 0,00540 + 
45. Gcr pathway 0,26946 0,01829 + 
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46. Glucose down 0,02384 0,13890 + 
47. Glucose up 0,05102 0,03448  
48. Glutation down 1,97555 E-08 9,42137 E-08  
49. Glutation up 0,00057 0,00004  
50. GO Ros 0,01204 0,04954  
51. Gpcr pathway 0,85403 0,01868 + 
52. Hdac pathway 0,69933 0,03376 + 
53. Hemo tf list jp 0,00033 0,00004  
54. Hoxa9 down 0,00059 0,00123  
55. Htert down 0,00006 0,00026  
56. Htert up 4,65167 E-08 0,00001  
57. Human CD34 enriched tf jp 0,00170 0,01360  
58. Ifng pathway 0,04859 0,03636  
59. Il 10 pathway 0,03549 0,02719  
60. Il 17 pathway 0,03549 0,09764 + 
61. Insulin 2f down 0,00107 0,00039  
62. Kras top100 control 0,04394 0,18741 + 
63. Kras top100 knockdown 0,000001 0.000002  
64. Lair pathway 0,00008 0,00038  
65. LDL pathway 0,04859 0,31314 + 
66. Leu down 1,88119 E-13 1,26000 E-08  
67. Leu up 0,00002 0,00002  
68. Lymphocyte pathway 0,00005 0,00419  
69. Map00100 sterol biosynthesis 0,00007 0,00954  
70. Map00240 pyrimidine metabolism 0,09689 0,02795 + 
71. Map00251 glutamate metabolism 0,01244 0,03636  
72. Map00260 glycine serine and thre 0,01717 0,15300 + 
73. Map00330 arginine and proline me 0,05102 0,03448  
74. Map00450 selenoamino acid metabo 0,02735 0,01777  
75. Map00480 glutathione metabolism 0,00009 0,00038  
76. Map00620 pyruvate metabolism 0,01466 0,09740 + 
77. Map00640 propanoate metabolism 0,03327 0,53098 + 
78. Map00670 one carbon pool by fola 0,03506 0,04844  
79. Map00970 aminoacyl tRNA biosynth 0,08183 0,00382 + 
80. Mapk pathway 0,01679 0,02225  
81. Mapkkk cascade 0,00587 0,00246  
82. Mef2d pathway 0,21545 0,01759 + 
83. Methionine pathway 0,02735 0,01829  
84. Monocyte pathway 0,00001 0,00096  
85. Mrna processing 0,00226 0,00069  
86. Mrna splicing 0,037736 0,07873 + 
87. Myc mut 0,02296 0,04577  
88. Neutrophil pathway 0,00007 0,00954  
89. NFAT pathway 0,53356 0,00260 + 
90. NFκB induced 0,00048 0,00486  
91. Nkt pathway 0,29413 0,04206 + 
92. Nos1 pathway 0,35976 0,00267 + 
93. p38 mapk pathway 0,00424 0,03516  
94. p53  hypoxia pathway 0,01759 0,06084 + 
95. p53 pathway 0,03549 0,02719  
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96. p53 signalling 0,00509 0,13494 + 
97. Parkin pathway 0,03506 0,43487 + 
98. Pentose phosphate pathway 0,04859 0,03980  
99. PGC 0,00616 0,10373 + 
100. Pitx2 pathway 0,00790 0,05132 + 
101. Ppara pathway 0,01645 0,16911 + 
102. Proliferation genes 0,01085 8,69721 E-05  
103. Proteasome degradation 0,01204 0,02662  
104. Proteasome pathway 0,00055 0,00002  
105. Raccycd pathway 0,39657 0,00742 + 
106. Radiation sensitivity 0,00881 0,09764 + 
107. Rap down 0,000004 0,00021  
108. Ras pathway 0,52782 0,03140 + 
109. Reck pathway 0,28772 0,00834 + 
110. Reelin pathway 0,02735 0,02220  
111. Set pathway 0,18377 0,04038 + 
112. Shh lisa 0,01759 0,00267  
113. Bcr signaling pathway 0,55225 0,00954  
114. CD40 pathway map 0,11990 0,00267 + 
115. Pip3 sigin cardiac myoctes 0,44721 0,04073 + 
116. Sig pip3 signalling in B lymphocytes 0,68685 0,01868 + 
117. Slrp2 pathway 0,01233 0,00765  
118. Erk1 erk2 mapk pathway 0,26992 0,01580 + 
119. Jnk mapk pathway 0,03598 0,02635  
120. p38 mapk pathway 0,00059 2,27987E-05  
121. Tel pathway 0,04850 0,05758 + 
122. TGF- β signaling pathway 0,01663 0,01031  
123. TGF-β pathway 0,00134 0,03474  
124. TNF and fas network 0,02488 0,02076  
125. Upreg by hoxa9 0,01606 0,00824  
126. Urea cycle pathway 0,22713 0,03980 + 
127. Vip pathway 0,50376 0,00087 + 
128. Voxphos 0,87114 0,02942 + 
129. Wnt pathway 0,00627 0,00373  
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Appendix 2 
 
     pathway  maoSMC 
P value 
stretch vs. static 
WT 
P value  
stretch vs. static 
zyxin -/- 
1. Adult liver vs fetal liver GNF2 0,26066                 0,01440 
2. Agpcr pathway 0,05868                 0,03212 
3. Akap96 pathway 0,02113                 0,08847 
4. Akap centrosome pathway 0,13273                 0,00084       + 
5. Androgen up genes  0,14135                 0,02004       + 
6. AP00120 bile acid biosynthesis 1,00000                 0,01598 
7. Arenrf2 pathway 0,01444                 0,04180 
8. Atm pathway 0,05868                 0,03212 
9. Bad pathway 0,05485                 0,02585 
10. Bcl2 family and regulatory network  0,03499                 0,65676       + 
11. Bcr pathway  0,00498                 0,09519 
12. Biopeptides pathway 0,00999                 0,31876       + 
13. BRCA down 0,00384                 0,00159 
14. Breast cancer estrogen signalling 0,01389                 0,09561       + 
15. Calcineurin pathway 0,04430                 0,30316       + 
16. Carm1 pathway 0,05868                 0,03212 
17. Ccr5 pathway 0,02009                 0,21899       + 
18. Cdmac pathway 0,04405                 0,13771       + 
19. Cell adhesion 0,39092                 0,00483       + 
20. Cell cycle checkpoint 0,04430                 0,30316       + 
21. Cell cycle regulator 0,02692                 0,62950       + 
22. Cell motility 0,28311                 0,05545       + 
23. Cftr pathway 0,23715                 0,00424       + 
24. Chemical pathway 0,05485                 0,10822       + 
25. Cilia proteins 0,00175                 0,01680 
26. Ck1pathway 0,07528                 0,00629       + 
27. CAM                                                                                         0,09004                 0,00102       + 
28. Cell cycle 0,01292                 0,05082 
29. Hormonal functions 0,05868                 0,16411       + 
30. Repair                                                                                         0,05485                 1,00000       + 
31. Signalling 0,03309                 0,00341 
32. Transcription factors 0,00095                 0,26161       + 
33. Transport 0,07155                 0,04646 
34. Creb pathway 0,00053                 0,00415 
35. Death pathway 0,81023                 0,00622       + 
36. DNA damage signalling  0,03486                 0,06538       + 
37. Downreg by HOXA9  0,28371                 0,00245       + 
38. Dream pathway 0,04405                 0,00020 
39. Egf pathway 0,03993                 0,06364       + 
40. Eif4 pathway 0,07962                 0,03869       + 
41. Electron_transporter_activity 0,21636                 0,00504       + 
42. EMT down  0,04072                 0,01440 
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43. EMT up  0,00923                 0,00892 
44. Epha4 pathway 0,04405                 0,49705     + 
45. Epon f kb pathway 0,01296                 0,36752     + 
46. Erbb4 pathway 0,00696                 1,00000     + 
47. Erk pathway 0,00289                 0,07345     + 
48. Fas pathway 0,53918                 0,04625     + 
49. Free pathway 0,32349                 0,02929     + 
50. Gata3 pathway 0,03499                 0,00242 
51. Gleevec pathway 6,1E-05                 0,12458     + 
52. Glucose up 0,04785                 0,00415 
53. Glutation down 0,00390                 0,08825     + 
54. Glutation up 7,9E-05                 0,00005 
55. GO ROS 0,03499                 0,01598 
56. HEMO TF list jp 0,00631                 0,42432     + 
57. Hif pathway 0,03150                 0,45712     + 
58. HOXA9 down 0,16047                 0,00528     + 
59. HTERT down 0,0004                   0,05687 
60. Human CD34 enriched TF JP 0,00104                 0,15889     + 
61. Human mito db62002 0,00089                 0,12195     + 
62. IGFL pathway 0,30901                 0,05277     + 
63. Il10 pathway 0,05868                 0,16411     + 
64. Il1 r pathway 0,07962                 0,00810     + 
65. Il22 bp pathway 0,04405                 0,49705     + 
66. Il6 pathway 0,00061                 0,24700     + 
67. INS                                                                                          0,00109                 0,76579     + 
68. Insulin 2f up 0,07626                 0,03694     + 
69. Keratinocyte pathway 0,01491                 0,00421 
70. KRAS TOP100 control 0,23960                 0,00051     + 
71. KRAS TOP100 knockdown 0,00049                 0,00977 
72. Krebs TCA cycle 0,05485                 0,70541     + 
73. LEU up  0,00031                 0,00044 
74. MAP kinase kinase activity 0,38647                 0,04646     + 
75. Malatex pathway  0,00080                 0,20469     + 
76. MAP00030 pentose phosphate pathway  0,00384                 0,45712     + 
77. MAP00051 fructose and mannose metabolism 0,03499                 0,65676     + 
78. MAP00062 fatty acid biosynthesis 0,04571                 0,26315     + 
79. MAP00240 pyrimidine metabolism 0,03993                 0,19731     + 
80. MAP00251 glutamate metabolism 0,00677                 0,07833 
81. MAP00252 alanine and aspartate metabolism 0,04430                 0,02055 
82. MAP00280 valine leucine and isoleucine 0,00601                 0,15967     + 
83. MAP00310 lysine degradation 0,02009                 0,6000       + 
84. MAP00330 arginine and proline metabolism 0,04785                 1,00000     + 
85. MAP00350 tyrosine metabolism 0,03286                 0,05457 
86. MAP00380 tryptophan metabolism 0,01024                 0,19731     + 
87. MAP00480 glutathione metabolism 0,05868                 0,00424     + 
88. MAP00632 benzoate degradation  0,04571                 1,00000     + 
89. MAP00640 propanoate metabolism  0,05485                 0,70541     + 
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90. MAP00860 porphyrin and chlorophy  0,02113                 0,08847 
91. MAP00970 aminoacyl tRNA biosynth 0,01444                 0,00067 
92. MAPK cascade 0,05277                 0,30901      + 
93. Mapk pathway  0,04874                 0,08453      + 
94. Mitochondr 0,00089                 0,03333 
95. mRNA processing  0,01299                 0,81380      + 
96. mRNA splicing  0,00383                 1,00000      + 
97. Mtor pathway 0,18166                 0,02585      + 
98. NFAT pathway 0,02951                 0,03103 
99. NGF pathway 0,09367                 0,05277      + 
100. No1 pathway 0,04785                 0,21687      + 
101. Nos1 pathway 0,11370                 0,01211      + 
102. Notch pathway 0,00696                 1,00000      + 
103. Nthi pathway 0,09367                 0,05277 
104. p38 mapk pathway  0,01623                 0,51218      + 
105. p53 UP  0,00018                 0,02790 
106. p53 hypoxiapathway 0,00036                 0,21899      + 
107. p53 pathway  0,01444                 0,00629 
108. PDGF pathway 0,00792                 0,01297 
109. PGC                                                                                          0,00772                 0,28276      + 
110. Plce pathway 0,20146                 0,02375 
111. Ppara pathway 0,00197                 0,00176 
112. Proliferation GENES  0,01374                 0,17233      + 
113. Ptdins pathway 0,00322                 0,12458      + 
114. Pyk2 pathway 0,04785                 0,21687      + 
115. PYR                                                                                          0,03150                 0,45712      + 
116. Rac1 pathway 0,05485                 0,02585 
117. Rac cycd pathway 0,09367                 0,05277      + 
118. Radiation sensitivity 0,04430                 0,09278 
119. RAP DOWN  0,00206                 0,00771 
120. RAP UP  0,00859                 0,47674      + 
121. RAR UP  0,05664                 0,00528 
122. B-cell receptor complexes 0,00601                 0,04625 
123. Bone morphogenetic 1,00000                 0,00539 
124. G1 and s phases  0,02113                 0,08847      + 
125. Pten pathway  0,02009                 1,00000      + 
126. Trka receptor  0,02692                 0,24700      + 
127. SHH pathway 0,30901                 0,05277      + 
128. BCR signalling pathway  0,00827                 0,32148      + 
129. Insulin receptor pathway in card  0,00473                 0,49936      + 
130. PIP3 signalling in B-lymphocythes 0,00186                 0,29808      + 
131. PIP3 siginalling in  cardiac myoctes  0,01576                 0,20618      + 
132. Regulation  of  the actin cytoskeleton  0,00498                 0,09519      + 
133. Slrp2 pathway 0,02435                 1,00000      + 
134. Differentiation pathway in PC 0,51471                 0,05773      + 
135. G protein independ 7 trans rec 0,32349                 0,02929      + 
136. Ga13 pathway  0,00803                 1,00000      + 
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137. Gaq pathway  0,03286                 1,00000      + 
138. Jak STAT pathway 0,38647                 0,04646      + 
139. Phosphoinositide 3 Kinase pathway 0,02428                 0,27748      + 
140. Stress pathway  0,02692                 0,01211 
141. Tall 1 pathway 0,38647                 0,04646      + 
142. Tel pathway 0,00036                 0,60007      + 
143. Tid pathway 0,01444                 0,56832 
144. Toll pathway 0,31012                 0,01602      + 
145. Tpo pathway 0,00446                 0,03869 
146. Trna synthetases  0,01444                 0,00067 
147. Tumor supressor 0,01263                 0,70541      + 
148. VEGF pathway 0,06664                 0,03189 
149. Vip pathway 0,01263                 0,00065 
150. Wnt signalling 0,00433                 0,01035 
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